Introducing: The World's First GLP-1 Gummy
Learn More
Medications
Weight Loss

How Long Has Semaglutide Been Around: A Timeline of Medical Innovation

Uncover the fascinating history of Semaglutide, from its initial discovery to its current status.

Overview

Struggling with diabetes or weight loss? Semaglutide, a groundbreaking GLP-1 medication, has transformed treatment. Uncover its journey from lab to patient success.

Semaglutide has emerged as a groundbreaking medication in the realm of diabetes management and weight loss. Its journey began in the early 2000s, but how long has semaglutide been around? This question has piqued the interest of many health-conscious individuals and patients seeking effective treatment options. Semaglutide's history is marked by extensive research, rigorous clinical trials, and a carefully navigated path to FDA approval.

This comprehensive guide delves into the origins of semaglutide, tracing its development from initial discovery to its current status as a widely prescribed medication. We'll explore key milestones in semaglutide's timeline, including its invention, clinical testing phases, and market debut as Ozempic® and Rybelsus®. Additionally, we'll examine semaglutide's expanding role in weight management, its impact on medical practices, and ongoing research that continues to shape its future in healthcare.

Key Takeaways

Semaglutide has made significant strides in the realm of diabetes management and weight loss since its inception in the early 2000s. This groundbreaking medication has a relatively short but impactful history. Ozempic®, a semaglutide-based drug, received FDA approval for diabetes treatment in December 2017 [1]. It quickly gained popularity and began to be prescribed off-label for weight loss.

The journey of semaglutide expanded further when Wegovy®, another semaglutide formulation, got FDA approval specifically for weight loss in June 2021 [1]. This approval marked a milestone in the medication's timeline, offering new options for individuals seeking effective weight management solutions.

Semaglutide's effectiveness stems from its role as a GLP-1 receptor agonist. It mimics the action of natural GLP-1 gastrointestinal hormone, influencing appetite, digestion, and ultimately contributing to weight loss [2]. Clinical trials have shown promising results, with participants experiencing an average reduction in body weight of 5-10 percent [3].

The medication typically starts to work within two weeks, but noticeable results often appear within 8-12 weeks of steady use [3]. For long-term users, weight loss of up to 15 percent has been observed over a year or more [3]. It's crucial to note that semaglutide is most effective when combined with a healthy lifestyle, including a balanced diet and regular exercise.

Clinically proven

weight loss treatment

whole body health treatment

Compounded Semaglutide

As low as  
$176
/mo
As low as  
$276
/mo
In stock
Limited supply
Semaglutide

Oral Semaglutide

As low as  
/mo
As low as  
/mo
$246/mo
$196/1st mo
$246/mo
In stock
Limited supply
Semaglutide

Compounded Semaglutide & MIC+B12

As low as  
$276
/mo
As low as  
$296
/mo
In stock
Limited supply
Semaglutide

Compounded Semaglutide & Sermorelin

As low as  
/mo
As low as  
$406
/mo
In stock
Limited supply
Semaglutide

Compounded Semaglutide & Sermorelin & MIC+B12

As low as  
/mo
As low as  
$476
/mo
In stock
Limited supply
Semaglutide

The Origins of Semaglutide Research

Origins in GLP-1 Research

The journey of semaglutide began in the 1970s when researchers Jens Juul Holst and Joel Habener started exploring the glucagon-like peptide-1 (GLP-1) hormone. Initially, their focus was on duodenal ulcer disease, but their work laid the foundation for future breakthroughs in diabetes and obesity treatments. In 1988, they discovered GLP-1's significant potency, which later earned them and Daniel Drucker the 2021 Warren Alpert Foundation Prize.

Key Milestones in Semaglutide Development

The development of semaglutide stemmed from earlier research on GLP-1 receptor agonists. In 1998, a team at Novo Nordisk, led by scientist Lotte Bjerre Knudsen, developed liraglutide, a GLP-1 receptor agonist for diabetes treatment. Building on this success, researchers at Novo Nordisk began working on semaglutide in the early 2000s as a longer-acting alternative to liraglutide.

Semaglutide's structure includes key modifications that enhance its effectiveness. These include the replacement of alanine with α-aminoisobutyric acid at position 8, which improves resistance to enzyme degradation, and the addition of a C18 fatty diacid to lysine at position 26, which prolongs its half-life in the body.

FDA Approval Timeline

The FDA approval process for semaglutide started with clinical trials in 2015. After rigorous testing, the FDA approved semaglutide for type 2 diabetes treatment in December 2017, under the brand name Ozempic® [1]. This approval was based on evidence from seven clinical trials involving 4,087 participants across 33 countries. The trials demonstrated semaglutide's effectiveness in reducing HbA1c levels and body weight compared to placebo and other antidiabetic medications.

Key Players in Semaglutide Development

Main Researchers and Companies Involved

The development of semaglutide involved several key players who made significant contributions to its journey. Novo Nordisk, a Danish pharmaceutical company, played a central role in bringing semaglutide to market. Lotte Bjerre Knudsen, chief scientific advisor at Novo Nordisk, was instrumental in overcoming early challenges in the drug's development. She figured out how to make the peptide last longer in the body, a crucial step in creating an effective medication [1].

Richard DiMarchi, Distinguished Professor of Biochemistry at Indiana University, also made vital contributions. He transformed thinking about the hormones this class of therapies should mimic, which was critical to their efficacy [1]. Together, Bjerre Knudsen and DiMarchi were the first authors on two pivotal patents filed in the 1990s that led to semaglutide's use for obesity treatment [1].

Their Motivations and Goals

The primary motivation behind semaglutide's development was to create an effective treatment for type 2 diabetes. Researchers like Bjerre Knudsen recognized its potential for weight loss early on. She noticed that GLP-1 receptor agonists not only increased insulin secretion but also reduced appetite in mice [1]. This observation sparked interest in pursuing significant weight loss with these drugs.

Despite facing skepticism about obesity as a disease, both Bjerre Knudsen and DiMarchi remained committed to their goals. They aimed to develop a medication that could effectively treat both diabetes and obesity, addressing two major health concerns simultaneously. Their perseverance led to the creation of semaglutide, which has since become a groundbreaking treatment for both conditions [1].

The Discovery Phase of Semaglutide

The journey of semaglutide began in the early 2000s, building upon earlier research on GLP-1 receptor agonists. Novo Nordisk, a Danish pharmaceutical company, played a central role in its development. The goal was to create a longer-acting alternative to liraglutide, which had been developed in 1998. Researchers faced the challenge of balancing a long plasma half-life with sufficient GLP-1 receptor affinity in the presence of albumin.

In 2012, Jesper Lau, Vice President of Diabetes Protein and Peptide Chemistry at Novo Nordisk, is credited with the invention of semaglutide. The discovery phase involved extensive preclinical studies and animal trials. In June 2008, a phase II clinical trial began studying semaglutide as a once-weekly diabetes therapy. This marked a significant milestone in the development of this groundbreaking medication.

One of the main challenges was finding the optimal combination of a fatty acid with high albumin affinity, attached to GLP-1 via a water-compatible chemical linker. This was crucial to ensure that the derivatized peptide had high GLP-1 receptor potency in the presence of albumin. Researchers systematically assessed several fatty acids and linkers to overcome this hurdle.

Preclinical studies in db/db mice demonstrated semaglutide's high potency and duration of action. A dose-response study confirmed its effectiveness, with an ED50 below 2 nmol/kg for blood glucose reduction 48 hours after subcutaneous dosing. These promising results led to semaglutide's selection for more comprehensive studies and subsequent clinical trials, paving the way for its eventual FDA approval and market debut.

Clinical Trials: Proving Semaglutides Efficacy

The journey of semaglutide through clinical trials has been marked by impressive results, particularly in its role as a glucose regulator for type 2 diabetes. The SUSTAIN program, consisting of multiple phase 3 trials, has been instrumental in demonstrating semaglutide's effectiveness. These studies compared semaglutide to both placebo and other diabetes medications, showcasing its superior ability to lower hemoglobin A1c (HbA1c) levels and reduce body weight.

In the SUSTAIN trials, semaglutide consistently outperformed other treatments. For instance, it showed greater HbA1c reductions (approximately -1.5%) and weight loss (about -4.5 kg) compared to various alternatives [1]. The medication proved its worth against established treatments like sitagliptin, exenatide ER, and insulin glargine, demonstrating better glycemic control and weight reduction.

Notably, the SUSTAIN 6 trial examined semaglutide's impact on cardiovascular outcomes. The results were impressive, showing a significant 26% lower risk of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke compared to placebo over two years [1]. This finding was crucial in establishing semaglutide's potential benefits beyond glucose regulation.

These clinical trials have been pivotal in shaping our understanding of how long semaglutide has been around and its effectiveness in managing type 2 diabetes.

The FDA Approval Journey

Semaglutide's journey to FDA approval culminated in a significant milestone on December 5, 2017, when Ozempic® received the green light for treating type 2 diabetes [1]. This approval marked the debut of semaglutide in the U.S. market, offering a new option for patients struggling with blood sugar control. Ozempic®, developed by Novo Nordisk, is an injectable form of semaglutide that's administered once weekly.

The FDA's decision was based on extensive clinical trials involving 4,087 patients across 33 countries [2]. These studies demonstrated Ozempic®'s effectiveness in lowering hemoglobin A1c levels, a key indicator of long-term blood sugar control. The trials compared Ozempic® to both placebo and other diabetes medications, showcasing its superior ability to regulate glucose levels.

Importantly, Ozempic®'s approval extended beyond just glycemic control. The FDA also recognized its potential to reduce cardiovascular risks in adults with type 2 diabetes and established heart disease [1]. This additional indication was supported by a separate trial involving 3,297 patients at high risk for cardiovascular events [2].

The approval of Ozempic® opened the door for further developments in semaglutide-based treatments. It paved the way for subsequent approvals of other formulations, including Rybelsus, an oral version of semaglutide, which got FDA approval in September 2019 [3]. This continuous evolution of semaglutide products has expanded treatment options for patients with type 2 diabetes, offering both injectable and oral alternatives.

Expanding Horizons: Semaglutide for Weight Loss

As semaglutide gained recognition for its effectiveness in managing type 2 diabetes, researchers began exploring its potential for weight management. This expansion of semaglutide's applications has opened new avenues for treating obesity, a condition that affects millions worldwide.

The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program has been instrumental in demonstrating semaglutide's efficacy for weight loss. In the STEP 1 trial, participants receiving once-weekly subcutaneous semaglutide 2.4 mg experienced a mean weight loss of 14.9% from baseline after 68 weeks, compared to 2.4% in the placebo group [1].

The STEP 5 trial, which assessed the long-term effects of semaglutide, showed even more promising results. After 104 weeks, participants in the semaglutide group achieved a mean weight loss of 15.2% from baseline, a significant difference of 12.6 percentage points compared to the placebo group [2]. This study demonstrated that the substantial weight loss observed in earlier trials could be maintained with continued semaglutide treatment for up to two years.

These impressive results led to the approval of semaglutide 2.4 mg (Wegovy®) for weight management in adults with obesity or overweight with at least one weight-related comorbidity in several countries, including the United States, Europe, and Canada [2].

Semaglutides Impact on Medical Practice

Semaglutide has made significant waves in the medical community, revolutionizing the treatment of type 2 diabetes and obesity. Since its introduction, this medication has become a top option for weight management when combined with lifestyle changes. Its effectiveness has been consistently demonstrated in clinical settings, with patients experiencing weight loss similar to that observed in randomized clinical trials.

In a cohort study, patients lost approximately 6.7 kg at 3 months and 12.3 kg at 6 months, equivalent to 5.9% and 10.9% of weight lost, respectively [4]. These results support the applicability of semaglutide in less controlled environments, proving its effectiveness beyond clinical trials.

The impact of semaglutide extends beyond weight loss. It has shown promise in reducing cardiovascular risks in adults with type 2 diabetes and established heart disease. This additional benefit has expanded its use in medical practice, making it a valuable tool for managing multiple health concerns simultaneously.

Semaglutide's once-weekly dosing schedule has the potential to improve patient adherence compared to daily therapies. While this wasn't directly evaluated in the STEP program, trials have shown improved adherence with once-weekly GLP-1 therapy for diabetes mellitus over once-daily therapy [5].

Despite its effectiveness, semaglutide's impact on medical practice is still evolving. Current obesity guidelines by major medical associations don't yet include semaglutide 2.4 mg, as these guidelines were published before its approval. As more data becomes available and guidelines are updated, semaglutide's role in medical practice is likely to become more prominent.

Recent Developments and Ongoing Research

The journey of semaglutide continues to evolve, with recent developments and ongoing research expanding its potential applications. In June 2021, the FDA approved higher doses of subcutaneous semaglutide (1.7 and 2.4 mg once weekly) for long-term weight management [1]. This approval was based on the impressive results from the Semaglutide Treatment Effect in People With Obesity (STEP) trials, which demonstrated the drug's efficacy in treating obesity [1].

A study published in November 2023 revealed that non-diabetic, overweight adults taking semaglutide for more than three years had a 20% lower risk of heart attack, stroke, or death resulting from cardiovascular disease [2]. This finding has significant implications for the future use of semaglutide in cardiovascular risk reduction.

Looking ahead, semaglutide's potential extends beyond weight management and diabetes treatment. Ongoing research is exploring its effects on kidney function, with promising results indicating its ability to combat kidney function decline in individuals with cardiovascular disease who are overweight or have obesity [2]. Additionally, studies are investigating semaglutide's potential in treating non-alcoholic fatty liver disease and obstructive sleep apnea in patients with obesity [3].

Final Thoughts

Semaglutide has made significant strides in the realm of diabetes management and weight loss since its introduction in the early 2000s. Its journey from initial research to FDA approval has been marked by rigorous clinical trials and groundbreaking discoveries. The medication's effectiveness in lowering blood sugar levels and promoting weight loss has led to its widespread use in medical practices, offering new hope to patients struggling with these health concerns.

If you're wondering how to get semaglutide cheap, there are several strategies to explore. Many individuals look for discount programs through pharmacies, coupons, or patient assistance programs that can help reduce the semaglutide cost. You can also compare prices across different online pharmacies to find the most affordable options. Additionally, some clinics or telemedicine providers offer more affordable access to semaglutide prescriptions. For those without insurance, researching these options can make a significant difference in affordability. Always ensure that you're purchasing from reputable sources to guarantee the quality and safety of the medication.

To get the most out of semaglutide, it’s important to combine its use with a healthy diet and regular exercise. While many semaglutide before and after pictures show impressive results, achieving and maintaining these outcomes requires commitment to lifestyle changes in addition to taking the medication. It’s equally important to be aware of who may not be a good candidate for this treatment. Who should not take semaglutide includes individuals with a personal or family history of thyroid cancer or those with certain endocrine disorders. The pros and cons of semaglutide for weight loss should be carefully weighed, as it offers significant benefits in appetite control and weight loss, but may also come with side effects like nausea or digestive discomfort. Consulting with a healthcare provider can help you determine whether semaglutide is the right option for you.

Looking ahead, semaglutide's potential extends beyond its current applications. Ongoing research is exploring its effects on cardiovascular health, kidney function, and other obesity-related conditions. As our understanding of semaglutide grows, it's likely to play an increasingly important role in addressing some of the most pressing health challenges of our time. While challenges remain, the future of semaglutide appears promising, with the potential to improve the lives of millions. 

Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.

References 

1. Kommu S, Whitfield P. Semaglutide. PubMed. Published 2024. Accessed October 21, 2024. https://www.ncbi.nlm.nih.gov/books/NBK603723/

2. Chao A, Wadden T. Semaglutide - an overview | ScienceDirect Topics. www.sciencedirect.com. Published 2023. Accessed October 21, 2024. https://www.sciencedirect.com/topics/medicine-and-dentistry/semaglutide

3. Canadian Agency for Drugs and Technologies in Health. Clinical Review Report: Semaglutide (Ozempic): (Novo Nordisk Canada Inc.): Indication: For the Treatment of Adult Patients with Type 2 Diabetes Mellitus to Improve Glycemic Control, in Combination with Metformin (Second-Line Treatment), and in Combination with Metformin and Sulfonylurea (Third-Line Treatment). Canadian Agency for Drugs and Technologies in Health; 2019. https://www.ncbi.nlm.nih.gov/books/NBK544009/

4. Ghusn W, De la Rosa A, Sacoto D, et al. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Network Open. 2022;5(9):e2231982. doi: https://doi.org/10.1001/jamanetworkopen.2022.31982

5. Fornes A, Huff J, Pritchard RI, Godfrey M. Once-Weekly Semaglutide for Weight Management: A Clinical Review. Journal of Pharmacy Technology. 2022;38(4):875512252210926. doi: https://doi.org/10.1177/87551225221092681

Clinically proven weight loss treatments

GLP-1 medications

Starting at $179/mo
No items found.

Start your health journey now

On-demand medical support, 100% online
Transparent pricing for every single dose
Tested lots for potency, sterility, pH and endotoxicity
Transparent pricing for every single dose
Weight Loss
How Long Has Semaglutide Been Around: A Timeline of Medical Innovation
Full name
December 13, 2024
5
 min read

The Origins of Semaglutide Research

Origins in GLP-1 Research

The journey of semaglutide began in the 1970s when researchers Jens Juul Holst and Joel Habener started exploring the glucagon-like peptide-1 (GLP-1) hormone. Initially, their focus was on duodenal ulcer disease, but their work laid the foundation for future breakthroughs in diabetes and obesity treatments. In 1988, they discovered GLP-1's significant potency, which later earned them and Daniel Drucker the 2021 Warren Alpert Foundation Prize.

Key Milestones in Semaglutide Development

The development of semaglutide stemmed from earlier research on GLP-1 receptor agonists. In 1998, a team at Novo Nordisk, led by scientist Lotte Bjerre Knudsen, developed liraglutide, a GLP-1 receptor agonist for diabetes treatment. Building on this success, researchers at Novo Nordisk began working on semaglutide in the early 2000s as a longer-acting alternative to liraglutide.

Semaglutide's structure includes key modifications that enhance its effectiveness. These include the replacement of alanine with α-aminoisobutyric acid at position 8, which improves resistance to enzyme degradation, and the addition of a C18 fatty diacid to lysine at position 26, which prolongs its half-life in the body.

FDA Approval Timeline

The FDA approval process for semaglutide started with clinical trials in 2015. After rigorous testing, the FDA approved semaglutide for type 2 diabetes treatment in December 2017, under the brand name Ozempic® [1]. This approval was based on evidence from seven clinical trials involving 4,087 participants across 33 countries. The trials demonstrated semaglutide's effectiveness in reducing HbA1c levels and body weight compared to placebo and other antidiabetic medications.

Key Players in Semaglutide Development

Main Researchers and Companies Involved

The development of semaglutide involved several key players who made significant contributions to its journey. Novo Nordisk, a Danish pharmaceutical company, played a central role in bringing semaglutide to market. Lotte Bjerre Knudsen, chief scientific advisor at Novo Nordisk, was instrumental in overcoming early challenges in the drug's development. She figured out how to make the peptide last longer in the body, a crucial step in creating an effective medication [1].

Richard DiMarchi, Distinguished Professor of Biochemistry at Indiana University, also made vital contributions. He transformed thinking about the hormones this class of therapies should mimic, which was critical to their efficacy [1]. Together, Bjerre Knudsen and DiMarchi were the first authors on two pivotal patents filed in the 1990s that led to semaglutide's use for obesity treatment [1].

Their Motivations and Goals

The primary motivation behind semaglutide's development was to create an effective treatment for type 2 diabetes. Researchers like Bjerre Knudsen recognized its potential for weight loss early on. She noticed that GLP-1 receptor agonists not only increased insulin secretion but also reduced appetite in mice [1]. This observation sparked interest in pursuing significant weight loss with these drugs.

Despite facing skepticism about obesity as a disease, both Bjerre Knudsen and DiMarchi remained committed to their goals. They aimed to develop a medication that could effectively treat both diabetes and obesity, addressing two major health concerns simultaneously. Their perseverance led to the creation of semaglutide, which has since become a groundbreaking treatment for both conditions [1].

The Discovery Phase of Semaglutide

The journey of semaglutide began in the early 2000s, building upon earlier research on GLP-1 receptor agonists. Novo Nordisk, a Danish pharmaceutical company, played a central role in its development. The goal was to create a longer-acting alternative to liraglutide, which had been developed in 1998. Researchers faced the challenge of balancing a long plasma half-life with sufficient GLP-1 receptor affinity in the presence of albumin.

In 2012, Jesper Lau, Vice President of Diabetes Protein and Peptide Chemistry at Novo Nordisk, is credited with the invention of semaglutide. The discovery phase involved extensive preclinical studies and animal trials. In June 2008, a phase II clinical trial began studying semaglutide as a once-weekly diabetes therapy. This marked a significant milestone in the development of this groundbreaking medication.

One of the main challenges was finding the optimal combination of a fatty acid with high albumin affinity, attached to GLP-1 via a water-compatible chemical linker. This was crucial to ensure that the derivatized peptide had high GLP-1 receptor potency in the presence of albumin. Researchers systematically assessed several fatty acids and linkers to overcome this hurdle.

Preclinical studies in db/db mice demonstrated semaglutide's high potency and duration of action. A dose-response study confirmed its effectiveness, with an ED50 below 2 nmol/kg for blood glucose reduction 48 hours after subcutaneous dosing. These promising results led to semaglutide's selection for more comprehensive studies and subsequent clinical trials, paving the way for its eventual FDA approval and market debut.

Clinical Trials: Proving Semaglutides Efficacy

The journey of semaglutide through clinical trials has been marked by impressive results, particularly in its role as a glucose regulator for type 2 diabetes. The SUSTAIN program, consisting of multiple phase 3 trials, has been instrumental in demonstrating semaglutide's effectiveness. These studies compared semaglutide to both placebo and other diabetes medications, showcasing its superior ability to lower hemoglobin A1c (HbA1c) levels and reduce body weight.

In the SUSTAIN trials, semaglutide consistently outperformed other treatments. For instance, it showed greater HbA1c reductions (approximately -1.5%) and weight loss (about -4.5 kg) compared to various alternatives [1]. The medication proved its worth against established treatments like sitagliptin, exenatide ER, and insulin glargine, demonstrating better glycemic control and weight reduction.

Notably, the SUSTAIN 6 trial examined semaglutide's impact on cardiovascular outcomes. The results were impressive, showing a significant 26% lower risk of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke compared to placebo over two years [1]. This finding was crucial in establishing semaglutide's potential benefits beyond glucose regulation.

These clinical trials have been pivotal in shaping our understanding of how long semaglutide has been around and its effectiveness in managing type 2 diabetes.

The FDA Approval Journey

Semaglutide's journey to FDA approval culminated in a significant milestone on December 5, 2017, when Ozempic® received the green light for treating type 2 diabetes [1]. This approval marked the debut of semaglutide in the U.S. market, offering a new option for patients struggling with blood sugar control. Ozempic®, developed by Novo Nordisk, is an injectable form of semaglutide that's administered once weekly.

The FDA's decision was based on extensive clinical trials involving 4,087 patients across 33 countries [2]. These studies demonstrated Ozempic®'s effectiveness in lowering hemoglobin A1c levels, a key indicator of long-term blood sugar control. The trials compared Ozempic® to both placebo and other diabetes medications, showcasing its superior ability to regulate glucose levels.

Importantly, Ozempic®'s approval extended beyond just glycemic control. The FDA also recognized its potential to reduce cardiovascular risks in adults with type 2 diabetes and established heart disease [1]. This additional indication was supported by a separate trial involving 3,297 patients at high risk for cardiovascular events [2].

The approval of Ozempic® opened the door for further developments in semaglutide-based treatments. It paved the way for subsequent approvals of other formulations, including Rybelsus, an oral version of semaglutide, which got FDA approval in September 2019 [3]. This continuous evolution of semaglutide products has expanded treatment options for patients with type 2 diabetes, offering both injectable and oral alternatives.

Expanding Horizons: Semaglutide for Weight Loss

As semaglutide gained recognition for its effectiveness in managing type 2 diabetes, researchers began exploring its potential for weight management. This expansion of semaglutide's applications has opened new avenues for treating obesity, a condition that affects millions worldwide.

The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program has been instrumental in demonstrating semaglutide's efficacy for weight loss. In the STEP 1 trial, participants receiving once-weekly subcutaneous semaglutide 2.4 mg experienced a mean weight loss of 14.9% from baseline after 68 weeks, compared to 2.4% in the placebo group [1].

The STEP 5 trial, which assessed the long-term effects of semaglutide, showed even more promising results. After 104 weeks, participants in the semaglutide group achieved a mean weight loss of 15.2% from baseline, a significant difference of 12.6 percentage points compared to the placebo group [2]. This study demonstrated that the substantial weight loss observed in earlier trials could be maintained with continued semaglutide treatment for up to two years.

These impressive results led to the approval of semaglutide 2.4 mg (Wegovy®) for weight management in adults with obesity or overweight with at least one weight-related comorbidity in several countries, including the United States, Europe, and Canada [2].

Semaglutides Impact on Medical Practice

Semaglutide has made significant waves in the medical community, revolutionizing the treatment of type 2 diabetes and obesity. Since its introduction, this medication has become a top option for weight management when combined with lifestyle changes. Its effectiveness has been consistently demonstrated in clinical settings, with patients experiencing weight loss similar to that observed in randomized clinical trials.

In a cohort study, patients lost approximately 6.7 kg at 3 months and 12.3 kg at 6 months, equivalent to 5.9% and 10.9% of weight lost, respectively [4]. These results support the applicability of semaglutide in less controlled environments, proving its effectiveness beyond clinical trials.

The impact of semaglutide extends beyond weight loss. It has shown promise in reducing cardiovascular risks in adults with type 2 diabetes and established heart disease. This additional benefit has expanded its use in medical practice, making it a valuable tool for managing multiple health concerns simultaneously.

Semaglutide's once-weekly dosing schedule has the potential to improve patient adherence compared to daily therapies. While this wasn't directly evaluated in the STEP program, trials have shown improved adherence with once-weekly GLP-1 therapy for diabetes mellitus over once-daily therapy [5].

Despite its effectiveness, semaglutide's impact on medical practice is still evolving. Current obesity guidelines by major medical associations don't yet include semaglutide 2.4 mg, as these guidelines were published before its approval. As more data becomes available and guidelines are updated, semaglutide's role in medical practice is likely to become more prominent.

Recent Developments and Ongoing Research

The journey of semaglutide continues to evolve, with recent developments and ongoing research expanding its potential applications. In June 2021, the FDA approved higher doses of subcutaneous semaglutide (1.7 and 2.4 mg once weekly) for long-term weight management [1]. This approval was based on the impressive results from the Semaglutide Treatment Effect in People With Obesity (STEP) trials, which demonstrated the drug's efficacy in treating obesity [1].

A study published in November 2023 revealed that non-diabetic, overweight adults taking semaglutide for more than three years had a 20% lower risk of heart attack, stroke, or death resulting from cardiovascular disease [2]. This finding has significant implications for the future use of semaglutide in cardiovascular risk reduction.

Looking ahead, semaglutide's potential extends beyond weight management and diabetes treatment. Ongoing research is exploring its effects on kidney function, with promising results indicating its ability to combat kidney function decline in individuals with cardiovascular disease who are overweight or have obesity [2]. Additionally, studies are investigating semaglutide's potential in treating non-alcoholic fatty liver disease and obstructive sleep apnea in patients with obesity [3].

Final Thoughts

Semaglutide has made significant strides in the realm of diabetes management and weight loss since its introduction in the early 2000s. Its journey from initial research to FDA approval has been marked by rigorous clinical trials and groundbreaking discoveries. The medication's effectiveness in lowering blood sugar levels and promoting weight loss has led to its widespread use in medical practices, offering new hope to patients struggling with these health concerns.

If you're wondering how to get semaglutide cheap, there are several strategies to explore. Many individuals look for discount programs through pharmacies, coupons, or patient assistance programs that can help reduce the semaglutide cost. You can also compare prices across different online pharmacies to find the most affordable options. Additionally, some clinics or telemedicine providers offer more affordable access to semaglutide prescriptions. For those without insurance, researching these options can make a significant difference in affordability. Always ensure that you're purchasing from reputable sources to guarantee the quality and safety of the medication.

To get the most out of semaglutide, it’s important to combine its use with a healthy diet and regular exercise. While many semaglutide before and after pictures show impressive results, achieving and maintaining these outcomes requires commitment to lifestyle changes in addition to taking the medication. It’s equally important to be aware of who may not be a good candidate for this treatment. Who should not take semaglutide includes individuals with a personal or family history of thyroid cancer or those with certain endocrine disorders. The pros and cons of semaglutide for weight loss should be carefully weighed, as it offers significant benefits in appetite control and weight loss, but may also come with side effects like nausea or digestive discomfort. Consulting with a healthcare provider can help you determine whether semaglutide is the right option for you.

Looking ahead, semaglutide's potential extends beyond its current applications. Ongoing research is exploring its effects on cardiovascular health, kidney function, and other obesity-related conditions. As our understanding of semaglutide grows, it's likely to play an increasingly important role in addressing some of the most pressing health challenges of our time. While challenges remain, the future of semaglutide appears promising, with the potential to improve the lives of millions. 

Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.

References 

1. Kommu S, Whitfield P. Semaglutide. PubMed. Published 2024. Accessed October 21, 2024. https://www.ncbi.nlm.nih.gov/books/NBK603723/

2. Chao A, Wadden T. Semaglutide - an overview | ScienceDirect Topics. www.sciencedirect.com. Published 2023. Accessed October 21, 2024. https://www.sciencedirect.com/topics/medicine-and-dentistry/semaglutide

3. Canadian Agency for Drugs and Technologies in Health. Clinical Review Report: Semaglutide (Ozempic): (Novo Nordisk Canada Inc.): Indication: For the Treatment of Adult Patients with Type 2 Diabetes Mellitus to Improve Glycemic Control, in Combination with Metformin (Second-Line Treatment), and in Combination with Metformin and Sulfonylurea (Third-Line Treatment). Canadian Agency for Drugs and Technologies in Health; 2019. https://www.ncbi.nlm.nih.gov/books/NBK544009/

4. Ghusn W, De la Rosa A, Sacoto D, et al. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Network Open. 2022;5(9):e2231982. doi: https://doi.org/10.1001/jamanetworkopen.2022.31982

5. Fornes A, Huff J, Pritchard RI, Godfrey M. Once-Weekly Semaglutide for Weight Management: A Clinical Review. Journal of Pharmacy Technology. 2022;38(4):875512252210926. doi: https://doi.org/10.1177/87551225221092681

Share this post

Subscribe to our newsletter

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Everyday Eden

Featured Treatments

*Only available if prescribed after an online consultation with a healthcare provider. *Benefits outlined on TryEden are based on third-party studies. Plans are offered as a subscription service which you can cancel at any time. *Actual product packaging may appear differently than shown. Physicians may prescribe compounded medications as needed to meet patient requirements or drug shortages. *The FDA does not review or approve any compounded medications for safety or effectiveness. *Has not been approved by the FDA for these uses but studies have shown benefits. Results may vary.

The Science

Supporting research citations are below

1. Ozempic®, a GLP-1 receptor agonist, is approved for improving blood sugar control in adults with type 2 diabetes when used alongside diet and exercise. Clinical trials showed it effectively lowers HbA1c and body weight, regardless of sex, race, or age. While offering significant benefits, it may cause side effects like gastrointestinal issues, with serious risks including pancreatitis and potential cancer based on animal studies. The drug's efficacy and side effect profile were consistent across diverse demographic groups. Trials involved over 4,000 participants worldwide, further highlighting its global applicability and safety profile for a broad patient population.

1. Ozempic®, a GLP-1 receptor agonist, is approved for improving blood sugar control in adults with type 2 diabetes when used alongside diet and exercise. Clinical trials showed it effectively lowers HbA1c and body weight, regardless of sex, race, or age. While offering significant benefits, it may cause side effects like gastrointestinal issues, with serious risks including pancreatitis and potential cancer based on animal studies. The drug's efficacy and side effect profile were consistent across diverse demographic groups. Trials involved over 4,000 participants worldwide, further highlighting its global applicability and safety profile for a broad patient population.

Should you seek a prescription item, Eden will facilitate arranging a consultation with a qualified healthcare provider. This professional will assess your suitability for the prescription item. If deemed suitable, a doctor may issue a prescription for the item, which can be filled at a partner pharmacy, unless you specify an alternative preference.

Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

GLP-1 Rx Gummies

*Compounded medications may be prescribed by physicians but have not been FDA regulated for safety, effectiveness, or quality. FDA-approved medicines containing semaglutide are available.

WARNING

Please contact your doctor ASAP and seek in-person care immediately if a side effect becomes problematic or you experience:

  • Severe nausea and/or vomiting resulting in dehydration -  it is important to stay well hydrated and drink plenty of fluids while on this medication.
  • Kidney problems/kidney failure - vomiting, nausea, diarrhea can cause dehydration and kidney issues and make kidney problems worse in individuals who have pre-existing kidney conditions; may sometimes lead to the need for hemodialysis.
  • Thyroid C-Cell Tumor: Trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath (see black box warning below).
  • Pancreatitis: Severe pain in your abdomen or back that will not go away.
  • Acute gallbladder disease - Pain in the middle or right upper stomach, fever, white parts of your eyes turn yellow or skin turns yellow, nausea/vomiting. If gallstones or inflammation of the gallbladder is suspected further studies are needed.
  • Hepatitis/Elevated liver enzymes/Jaundice
  • Diabetic retinopathy problems: Changes in vision in those with type II diabetes, particularly vision problems may worsen in those with a history of diabetic retinopathy.
  • Severe gastrointestinal disease - may cause gastrointestinal disease; do not use if you have a history of severe gastrointestinal disease
  • Signs of low blood sugar (for example, dizziness, weakness, shakiness, jitteriness, headache, anxiety/mood changes, rapid heartbeat, confusion, slurred speech, sweating, or lightheadedness). While this is rare with GLP-1s, if it occurs, please seek in-person care immediately. If you have these symptoms, try having liquid or food containing sugar (around 15-20 grams) —drinking juice, having regular soda, or eating some hard candies right away, as this will help raise your blood sugar quickly. If taken with insulin or an insulin secretagogue (i.e. sulfonylurea such as Glipizide, glimepiride, and glyburide) it is best to talk to your healthcare provider about possibly lowering the dose of these medications to lower the risk of hypoglycemia.
  • Increasing heart rate
  • Worsening depression, behavior changes, or suicidality
  • Never share the semaglutide with other people

Drug Interactions

As with other medications, oral semaglutide can interact with alcohol and certain prescription and non-prescription medications and herbal products. The risk of hypoglycemia is increased when combined with insulin or insulin secretagogues such as sulfonylureas. Oral semaglutide delays gastric emptying and may impact the absorption of oral medications. If you are on thyroid hormone medication, prior to starting oral semaglutide, please review the timing of taking your thyroid hormone medication with the doctor who prescribes it as it may need to be adjusted. The drug levels of medications with narrow therapeutic windows (ie warfarin) should be monitored closely while on oral semaglutide.

Please consult the pharmaceutical packaging for a full list of side effects, warnings, interactions and additional information.

To report suspected adverse reactions to o semaglutide, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

In case of emergencies, please call 911 or go to the nearest emergency room.

Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Compounded Semaglutide

*Compounded medications may be prescribed by physicians but have not been FDA regulated for safety, effectiveness, or quality. FDA-approved medicines containing semaglutide are available.

WARNING

Please contact your doctor ASAP and seek in-person care immediately if a side effect becomes problematic or you experience:

  • Severe nausea and/or vomiting resulting in dehydration—it is important to stay well hydrated and drink plenty of fluids while on this medication
    Kidney problems/kidney failure - vomiting, nausea, diarrhea can cause dehydration and kidney issues and make kidney problems worse in individuals who have pre-existing kidney conditions; may sometimes lead to the need for hemodialysis
  • Thyroid C-Cell Tumor: Trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath (see black box warning below)
  • Pancreatitis: Severe pain in your abdomen or back that will not go away
  • Acute gallbladder disease - Pain in the middle or right upper stomach, fever, white parts of your eyes turn yellow or skin turns yellow, nausea/vomiting. If gallstones or inflammation of the gallbladder is suspected further studies are needed.
  • Hepatitis/Elevated liver enzymes/Jaundice
  • Diabetic retinopathy problems: Changes in vision in those with type II diabetes, particularly vision problems may worsen in those with a history of diabetic retinopathy
  • Severe gastrointestinal disease - may cause gastrointestinal disease; do not use if you have a history of severe gastrointestinal disease
  • Signs of low blood sugar (for example, dizziness, weakness, shakiness, jitteriness, headache, anxiety/mood changes, rapid heartbeat, confusion, slurred speech, sweating, or lightheadedness). While this is rare with GLP-1s, if it occurs, please seek in-person care immediately. If you have these symptoms, try having liquid or food containing sugar (around 15-20 grams) —drinking juice, having regular soda, or eating some hard candies right away, as this will help raise your blood sugar quickly. If taken with insulin or an insulin secretagogue (i.e. sulfonylurea such as Glipizide, glimepiride, and glyburide) it is best to talk to your healthcare provider about possibly lowering the dose of these medications to lower the risk of hypoglycemia.
  • Increasing heart rate
  • Worsening depression, behavior changes, or suicidality

Never share the semaglutide with other people

Drug Interactions

As with other medications, compounded semaglutide can interact with alcohol and certain prescription and non-prescription medications and herbal products. The risk of hypoglycemia is increased when combined with insulin or insulin secretagogues such as sulfonylureas. Compounded semaglutide delays gastric emptying and may impact the absorption of oral medications. If you are on papillary hormone medication, prior to starting compounded semaglutide, please review the timing of taking your papillary hormone medication with the doctor who prescribes it as it may need to be adjusted. The drug levels of medications with narrow therapeutic windows (ie warfarin) should be monitored closely while on compounded semaglutide.

Please consult the pharmaceutical packaging for a full list of side effects, warnings, interactions and additional information.

To report suspected adverse reactions to compounded semaglutide, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

In case of emergencies, please call 911 or go to the nearest emergency room.

Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

BLACK BOX WARNING

GLP-1s are contraindicated in individuals with a history of medullary thyroid carcinoma, a family history of such, or in patients with multiple endocrine neoplasia syndrome type 2. Do not take them if you have ever had thyroid cancer. In studies with rodents, GLP-1s caused thyroid tumors, including thyroid cancer; it is not known if they will cause thyroid tumors or cancer in humans. Please notify your doctor ASAP if you develop trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath.

If you experience a medical emergency, call 911 or go to the nearest emergency room.

Tell your healthcare provider about your medical history prior to taking semaglutide.

Avoid alcohol while taking this medication. If you’re taking diabetes medications, please discuss this with your prescribing doctor before starting semaglutide, as your diabetes medications may need to be adjusted as you lose weight.

Use adequate contraception while taking this medication. Do not take this medication if pregnant, trying to get pregnant or breastfeeding. If you plan to become pregnant, this medication needs to be stopped at least 2 months before trying. This medication may cause fetal harm.

Notify your doctor if you have kidney, liver, or pancreas problems.

Stop using semaglutide and call your healthcare provider immediately if you have severe stomach or abdomen pain that will not go away, with or without vomiting.

Stop using semaglutide and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat.

Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue semaglutide if suspected and promptly seek medical advice.

Sermorelin

Safety Information:

Side effects are typically mild and go away over time.

Common side effects:

  • Pain, redness, or swelling at the place of injection

Rare side effects:

  • Itching
  • Trouble swallowing
  • Dizziness
  • Flushing
  • Headache
  • Sleepiness
  • Trouble sitting still

You shouldn't use Sermorelin if:

  • You have hypersensitivity to Sermorelin or any of its ingredients
  • You're pregnant
  • You're breastfeeding
  • You have active cancer

Precautions:

Regular monitoring of growth hormone levels, blood sugar levels, and overall health by a healthcare provider is recommended.

Note: The statements above have not been reviewed by the Food and Drug Administration. This product is not designed to diagnose, treat, cure, or prevent any condition.

Compounded Semaglutide

*Compounded medications may be prescribed by physicians but have not been FDA regulated for safety, effectiveness, or quality. FDA-approved medicines containing semaglutide are available.

WARNING

Please contact your doctor ASAP and seek in-person care immediately if a side effect becomes problematic or you experience:

  • Severe nausea and/or vomiting resulting in dehydration—it is important to stay well hydrated and drink plenty of fluids while on this medication
    Kidney problems/kidney failure - vomiting, nausea, diarrhea can cause dehydration and kidney issues and make kidney problems worse in individuals who have pre-existing kidney conditions; may sometimes lead to the need for hemodialysis
  • Thyroid C-Cell Tumor: Trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath (see black box warning below)
  • Pancreatitis: Severe pain in your abdomen or back that will not go away
  • Acute gallbladder disease - Pain in the middle or right upper stomach, fever, white parts of your eyes turn yellow or skin turns yellow, nausea/vomiting. If gallstones or inflammation of the gallbladder is suspected further studies are needed.
  • Hepatitis/Elevated liver enzymes/Jaundice
  • Diabetic retinopathy problems: Changes in vision in those with type II diabetes, particularly vision problems may worsen in those with a history of diabetic retinopathy
  • Severe gastrointestinal disease - may cause gastrointestinal disease; do not use if you have a history of severe gastrointestinal disease
  • Signs of low blood sugar (for example, dizziness, weakness, shakiness, jitteriness, headache, anxiety/mood changes, rapid heartbeat, confusion, slurred speech, sweating, or lightheadedness). While this is rare with GLP-1s, if it occurs, please seek in-person care immediately. If you have these symptoms, try having liquid or food containing sugar (around 15-20 grams) —drinking juice, having regular soda, or eating some hard candies right away, as this will help raise your blood sugar quickly. If taken with insulin or an insulin secretagogue (i.e. sulfonylurea such as Glipizide, glimepiride, and glyburide) it is best to talk to your healthcare provider about possibly lowering the dose of these medications to lower the risk of hypoglycemia.
  • Increasing heart rate
  • Worsening depression, behavior changes, or suicidality

Never share the semaglutide with other people

Drug Interactions

As with other medications, compounded semaglutide can interact with alcohol and certain prescription and non-prescription medications and herbal products. The risk of hypoglycemia is increased when combined with insulin or insulin secretagogues such as sulfonylureas. Compounded semaglutide delays gastric emptying and may impact the absorption of oral medications. If you are on papillary hormone medication, prior to starting compounded semaglutide, please review the timing of taking your papillary hormone medication with the doctor who prescribes it as it may need to be adjusted. The drug levels of medications with narrow therapeutic windows (ie warfarin) should be monitored closely while on compounded semaglutide.

Please consult the pharmaceutical packaging for a full list of side effects, warnings, interactions and additional information.

To report suspected adverse reactions to compounded semaglutide, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

In case of emergencies, please call 911 or go to the nearest emergency room.

Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

BLACK BOX WARNING

GLP-1s are contraindicated in individuals with a history of medullary thyroid carcinoma, a family history of such, or in patients with multiple endocrine neoplasia syndrome type 2. Do not take them if you have ever had thyroid cancer. In studies with rodents, GLP-1s caused thyroid tumors, including thyroid cancer; it is not known if they will cause thyroid tumors or cancer in humans. Please notify your doctor ASAP if you develop trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath.

If you experience a medical emergency, call 911 or go to the nearest emergency room.

Tell your healthcare provider about your medical history prior to taking semaglutide.

Avoid alcohol while taking this medication. If you’re taking diabetes medications, please discuss this with your prescribing doctor before starting semaglutide, as your diabetes medications may need to be adjusted as you lose weight.

Use adequate contraception while taking this medication. Do not take this medication if pregnant, trying to get pregnant or breastfeeding. If you plan to become pregnant, this medication needs to be stopped at least 2 months before trying. This medication may cause fetal harm.

Notify your doctor if you have kidney, liver, or pancreas problems.

Stop using semaglutide and call your healthcare provider immediately if you have severe stomach or abdomen pain that will not go away, with or without vomiting.

Stop using semaglutide and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat.

Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue semaglutide if suspected and promptly seek medical advice.

Sermorelin

Safety Information:

Side effects are typically mild and go away over time.

Common side effects:

  • Pain, redness, or swelling at the place of injection

Rare side effects:

  • Itching
  • Trouble swallowing
  • Dizziness
  • Flushing
  • Headache
  • Sleepiness
  • Trouble sitting still

You shouldn't use Sermorelin if:

  • You have hypersensitivity to Sermorelin or any of its ingredients
  • You're pregnant
  • You're breastfeeding
  • You have active cancer

Precautions:

Regular monitoring of growth hormone levels, blood sugar levels, and overall health by a healthcare provider is recommended.

Note: The statements above have not been reviewed by the Food and Drug Administration. This product is not designed to diagnose, treat, cure, or prevent any condition.

MIC+B12

Safety Information:

Side effects are typically mild and go away over time.

Common side effects:

  • Discomfort or redness at the injection area
  • Skin itching or sensations of overall swelling  
  • Muscular cramps and weakness
  • Nausea and issues with urination
  • Swelling around the ankles or feet  
  • Excessive fatigue

Precautions:

  • Avoid using B12/MIC if you are pregnant, nursing, or if you are planning to become pregnant or to breastfeed.
  • Should itching/irritation persist, consider using an over-the-counter anti-itch cream containing hydrocortisone, or stop using the product altogether.
  • In the uncommon event of more severe reactions, such as an irregular heartbeat or difficulty breathing, cease usage immediately and consult your healthcare provider.

Note: The statements above have not been reviewed by the Food and Drug Administration. This product is not designed to diagnose, treat, cure, or prevent any condition.

Sermorelin

Safety Information:

Side effects are typically mild and go away over time.

Common side effects:

  • Pain, redness, or swelling at the place of injection

Rare side effects:

  • Itching
  • Trouble swallowing
  • Dizziness
  • Flushing
  • Headache
  • Sleepiness
  • Trouble sitting still

You shouldn't use Sermorelin if:

  • You have hypersensitivity to Sermorelin or any of its ingredients
  • You're pregnant
  • You're breastfeeding
  • You have active cancer

Precautions:

Regular monitoring of growth hormone levels, blood sugar levels, and overall health by a healthcare provider is recommended.

Note: The statements above have not been reviewed by the Food and Drug Administration. This product is not designed to diagnose, treat, cure, or prevent any condition.

Vardenafil+Tadalafil

Common side effects:

  • Headache
  • Flushing
  • Nasal Congestion
  • Indigestion
  • Back Pain (more common with tadalafil)
  • Muscle Aches
  • Visual Disturbances (blurred vision, changes in color vision)

More serious, but less common side effects:

  • Hypotension: A significant drop in blood pressure, especially when combined with nitrates or certain other medications.
  • Cardiovascular Events: Risk of heart attack, stroke, or arrhythmias, particularly in individuals with pre-existing heart conditions.
  • Priapism: Prolonged erection lasting more than 4 hours, requiring medical attention.
  • Hearing Loss: Sudden decrease or loss of hearing.
  • Vision Loss: Rare cases of non-arteritic anterior ischemic optic neuropathy (NAION).

See an all inclusive list of side effects from Mayo Clinic.

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Monitoring Plan

To ensure your safety and the effectiveness of the treatment, regular monitoring will be required, including:

  • Baseline Testing:
    • Evaluation of current medications to assess for potential drug interactions.
  • Ongoing Monitoring:
    • Periodic assessments for side effects or adverse reactions.
  • Symptom Assessment:
    • Monitoring for any cardiovascular symptoms during exercise.
    • Reporting any visual or hearing changes immediately.
  • Follow-Up Visits:
    • Scheduled appointments to discuss your progress and address any concerns.

Contraindications:

Do not use Vardenafil or Tadalafil with nitrate medications, as this can cause a dangerous drop in blood pressure.  Do not use with other ED medications. Avoid use if you have serious heart conditions. Avoid use with NO boosters (separate use by at least 2 hours).

Precautions:

Consult your healthcare provider if you have cardiovascular disease, liver or kidney dysfunction, or a history of stroke.

Note: The statements above have not been reviewed by the Food and Drug Administration. This product is not designed to diagnose, treat, cure, or prevent any condition.

Sermorelin

Safety Information:

Side effects are typically mild and go away over time.

Common side effects:

  • Pain, redness, or swelling at the place of injection

Rare side effects:

  • Itching
  • Trouble swallowing
  • Dizziness
  • Flushing
  • Headache
  • Sleepiness
  • Trouble sitting still

You shouldn't use Sermorelin if:

  • You have hypersensitivity to Sermorelin or any of its ingredients
  • You're pregnant
  • You're breastfeeding
  • You have active cancer

Precautions:

Regular monitoring of growth hormone levels, blood sugar levels, and overall health by a healthcare provider is recommended.

Note: The statements above have not been reviewed by the Food and Drug Administration. This product is not designed to diagnose, treat, cure, or prevent any condition.

Vardenafil+Tadalafil

Common side effects:

  • Headache
  • Flushing
  • Nasal Congestion
  • Indigestion
  • Back Pain (more common with tadalafil)
  • Muscle Aches
  • Visual Disturbances (blurred vision, changes in color vision)

More serious, but less common side effects:

  • Hypotension: A significant drop in blood pressure, especially when combined with nitrates or certain other medications.
  • Cardiovascular Events: Risk of heart attack, stroke, or arrhythmias, particularly in individuals with pre-existing heart conditions.
  • Priapism: Prolonged erection lasting more than 4 hours, requiring medical attention.
  • Hearing Loss: Sudden decrease or loss of hearing.
  • Vision Loss: Rare cases of non-arteritic anterior ischemic optic neuropathy (NAION).

See an all inclusive list of side effects from Mayo Clinic.

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Monitoring Plan

To ensure your safety and the effectiveness of the treatment, regular monitoring will be required, including:

  • Baseline Testing:
    • Evaluation of current medications to assess for potential drug interactions.
  • Ongoing Monitoring:
    • Periodic assessments for side effects or adverse reactions.
  • Symptom Assessment:
    • Monitoring for any cardiovascular symptoms during exercise.
    • Reporting any visual or hearing changes immediately.
  • Follow-Up Visits:
    • Scheduled appointments to discuss your progress and address any concerns.

Contraindications:

Do not use Vardenafil or Tadalafil with nitrate medications, as this can cause a dangerous drop in blood pressure.  Do not use with other ED medications. Avoid use if you have serious heart conditions. Avoid use with NO boosters (separate use by at least 2 hours).

Precautions:

Consult your healthcare provider if you have cardiovascular disease, liver or kidney dysfunction, or a history of stroke.

Note: The statements above have not been reviewed by the Food and Drug Administration. This product is not designed to diagnose, treat, cure, or prevent any condition.

Compounded Semaglutide

*Compounded medications may be prescribed by physicians but have not been FDA regulated for safety, effectiveness, or quality. FDA-approved medicines containing semaglutide are available.

WARNING

Please contact your doctor ASAP and seek in-person care immediately if a side effect becomes problematic or you experience:

  • Severe nausea and/or vomiting resulting in dehydration—it is important to stay well hydrated and drink plenty of fluids while on this medication
    Kidney problems/kidney failure - vomiting, nausea, diarrhea can cause dehydration and kidney issues and make kidney problems worse in individuals who have pre-existing kidney conditions; may sometimes lead to the need for hemodialysis
  • Thyroid C-Cell Tumor: Trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath (see black box warning below)
  • Pancreatitis: Severe pain in your abdomen or back that will not go away
  • Acute gallbladder disease - Pain in the middle or right upper stomach, fever, white parts of your eyes turn yellow or skin turns yellow, nausea/vomiting. If gallstones or inflammation of the gallbladder is suspected further studies are needed.
  • Hepatitis/Elevated liver enzymes/Jaundice
  • Diabetic retinopathy problems: Changes in vision in those with type II diabetes, particularly vision problems may worsen in those with a history of diabetic retinopathy
  • Severe gastrointestinal disease - may cause gastrointestinal disease; do not use if you have a history of severe gastrointestinal disease
  • Signs of low blood sugar (for example, dizziness, weakness, shakiness, jitteriness, headache, anxiety/mood changes, rapid heartbeat, confusion, slurred speech, sweating, or lightheadedness). While this is rare with GLP-1s, if it occurs, please seek in-person care immediately. If you have these symptoms, try having liquid or food containing sugar (around 15-20 grams) —drinking juice, having regular soda, or eating some hard candies right away, as this will help raise your blood sugar quickly. If taken with insulin or an insulin secretagogue (i.e. sulfonylurea such as Glipizide, glimepiride, and glyburide) it is best to talk to your healthcare provider about possibly lowering the dose of these medications to lower the risk of hypoglycemia.
  • Increasing heart rate
  • Worsening depression, behavior changes, or suicidality

Never share the semaglutide with other people

Drug Interactions

As with other medications, compounded semaglutide can interact with alcohol and certain prescription and non-prescription medications and herbal products. The risk of hypoglycemia is increased when combined with insulin or insulin secretagogues such as sulfonylureas. Compounded semaglutide delays gastric emptying and may impact the absorption of oral medications. If you are on papillary hormone medication, prior to starting compounded semaglutide, please review the timing of taking your papillary hormone medication with the doctor who prescribes it as it may need to be adjusted. The drug levels of medications with narrow therapeutic windows (ie warfarin) should be monitored closely while on compounded semaglutide.

Please consult the pharmaceutical packaging for a full list of side effects, warnings, interactions and additional information.

To report suspected adverse reactions to compounded semaglutide, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

In case of emergencies, please call 911 or go to the nearest emergency room.

Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

BLACK BOX WARNING

GLP-1s are contraindicated in individuals with a history of medullary thyroid carcinoma, a family history of such, or in patients with multiple endocrine neoplasia syndrome type 2. Do not take them if you have ever had thyroid cancer. In studies with rodents, GLP-1s caused thyroid tumors, including thyroid cancer; it is not known if they will cause thyroid tumors or cancer in humans. Please notify your doctor ASAP if you develop trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath.

If you experience a medical emergency, call 911 or go to the nearest emergency room.

Tell your healthcare provider about your medical history prior to taking semaglutide.

Avoid alcohol while taking this medication. If you’re taking diabetes medications, please discuss this with your prescribing doctor before starting semaglutide, as your diabetes medications may need to be adjusted as you lose weight.

Use adequate contraception while taking this medication. Do not take this medication if pregnant, trying to get pregnant or breastfeeding. If you plan to become pregnant, this medication needs to be stopped at least 2 months before trying. This medication may cause fetal harm.

Notify your doctor if you have kidney, liver, or pancreas problems.

Stop using semaglutide and call your healthcare provider immediately if you have severe stomach or abdomen pain that will not go away, with or without vomiting.

Stop using semaglutide and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat.

Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue semaglutide if suspected and promptly seek medical advice.

Sermorelin

Safety Information:

Side effects are typically mild and go away over time.

Common side effects:

  • Pain, redness, or swelling at the place of injection

Rare side effects:

  • Itching
  • Trouble swallowing
  • Dizziness
  • Flushing
  • Headache
  • Sleepiness
  • Trouble sitting still

You shouldn't use Sermorelin if:

  • You have hypersensitivity to Sermorelin or any of its ingredients
  • You're pregnant
  • You're breastfeeding
  • You have active cancer

Precautions:

Regular monitoring of growth hormone levels, blood sugar levels, and overall health by a healthcare provider is recommended.

Note: The statements above have not been reviewed by the Food and Drug Administration. This product is not designed to diagnose, treat, cure, or prevent any condition.

Compounded Semaglutide

*Compounded medications may be prescribed by physicians but have not been FDA regulated for safety, effectiveness, or quality. FDA-approved medicines containing semaglutide are available.

WARNING

Please contact your doctor ASAP and seek in-person care immediately if a side effect becomes problematic or you experience:

  • Severe nausea and/or vomiting resulting in dehydration—it is important to stay well hydrated and drink plenty of fluids while on this medication
    Kidney problems/kidney failure - vomiting, nausea, diarrhea can cause dehydration and kidney issues and make kidney problems worse in individuals who have pre-existing kidney conditions; may sometimes lead to the need for hemodialysis
  • Thyroid C-Cell Tumor: Trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath (see black box warning below)
  • Pancreatitis: Severe pain in your abdomen or back that will not go away
  • Acute gallbladder disease - Pain in the middle or right upper stomach, fever, white parts of your eyes turn yellow or skin turns yellow, nausea/vomiting. If gallstones or inflammation of the gallbladder is suspected further studies are needed.
  • Hepatitis/Elevated liver enzymes/Jaundice
  • Diabetic retinopathy problems: Changes in vision in those with type II diabetes, particularly vision problems may worsen in those with a history of diabetic retinopathy
  • Severe gastrointestinal disease - may cause gastrointestinal disease; do not use if you have a history of severe gastrointestinal disease
  • Signs of low blood sugar (for example, dizziness, weakness, shakiness, jitteriness, headache, anxiety/mood changes, rapid heartbeat, confusion, slurred speech, sweating, or lightheadedness). While this is rare with GLP-1s, if it occurs, please seek in-person care immediately. If you have these symptoms, try having liquid or food containing sugar (around 15-20 grams) —drinking juice, having regular soda, or eating some hard candies right away, as this will help raise your blood sugar quickly. If taken with insulin or an insulin secretagogue (i.e. sulfonylurea such as Glipizide, glimepiride, and glyburide) it is best to talk to your healthcare provider about possibly lowering the dose of these medications to lower the risk of hypoglycemia.
  • Increasing heart rate
  • Worsening depression, behavior changes, or suicidality

Never share the semaglutide with other people

Drug Interactions

As with other medications, compounded semaglutide can interact with alcohol and certain prescription and non-prescription medications and herbal products. The risk of hypoglycemia is increased when combined with insulin or insulin secretagogues such as sulfonylureas. Compounded semaglutide delays gastric emptying and may impact the absorption of oral medications. If you are on papillary hormone medication, prior to starting compounded semaglutide, please review the timing of taking your papillary hormone medication with the doctor who prescribes it as it may need to be adjusted. The drug levels of medications with narrow therapeutic windows (ie warfarin) should be monitored closely while on compounded semaglutide.

Please consult the pharmaceutical packaging for a full list of side effects, warnings, interactions and additional information.

To report suspected adverse reactions to compounded semaglutide, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

In case of emergencies, please call 911 or go to the nearest emergency room.

Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

BLACK BOX WARNING

GLP-1s are contraindicated in individuals with a history of medullary thyroid carcinoma, a family history of such, or in patients with multiple endocrine neoplasia syndrome type 2. Do not take them if you have ever had thyroid cancer. In studies with rodents, GLP-1s caused thyroid tumors, including thyroid cancer; it is not known if they will cause thyroid tumors or cancer in humans. Please notify your doctor ASAP if you develop trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath.

If you experience a medical emergency, call 911 or go to the nearest emergency room.

Tell your healthcare provider about your medical history prior to taking semaglutide.

Avoid alcohol while taking this medication. If you’re taking diabetes medications, please discuss this with your prescribing doctor before starting semaglutide, as your diabetes medications may need to be adjusted as you lose weight.

Use adequate contraception while taking this medication. Do not take this medication if pregnant, trying to get pregnant or breastfeeding. If you plan to become pregnant, this medication needs to be stopped at least 2 months before trying. This medication may cause fetal harm.

Notify your doctor if you have kidney, liver, or pancreas problems.

Stop using semaglutide and call your healthcare provider immediately if you have severe stomach or abdomen pain that will not go away, with or without vomiting.

Stop using semaglutide and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat.

Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue semaglutide if suspected and promptly seek medical advice.

Sermorelin

Safety Information:

Side effects are typically mild and go away over time.

Common side effects:

  • Pain, redness, or swelling at the place of injection

Rare side effects:

  • Itching
  • Trouble swallowing
  • Dizziness
  • Flushing
  • Headache
  • Sleepiness
  • Trouble sitting still

You shouldn't use Sermorelin if:

  • You have hypersensitivity to Sermorelin or any of its ingredients
  • You're pregnant
  • You're breastfeeding
  • You have active cancer

Precautions:

Regular monitoring of growth hormone levels, blood sugar levels, and overall health by a healthcare provider is recommended.

Note: The statements above have not been reviewed by the Food and Drug Administration. This product is not designed to diagnose, treat, cure, or prevent any condition.

Compounded Semaglutide

*Compounded medications may be prescribed by physicians but have not been FDA regulated for safety, effectiveness, or quality. FDA-approved medicines containing semaglutide are available.

WARNING

Please contact your doctor ASAP and seek in-person care immediately if a side effect becomes problematic or you experience:

  • Severe nausea and/or vomiting resulting in dehydration—it is important to stay well hydrated and drink plenty of fluids while on this medication
    Kidney problems/kidney failure - vomiting, nausea, diarrhea can cause dehydration and kidney issues and make kidney problems worse in individuals who have pre-existing kidney conditions; may sometimes lead to the need for hemodialysis
  • Thyroid C-Cell Tumor: Trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath (see black box warning below)
  • Pancreatitis: Severe pain in your abdomen or back that will not go away
  • Acute gallbladder disease - Pain in the middle or right upper stomach, fever, white parts of your eyes turn yellow or skin turns yellow, nausea/vomiting. If gallstones or inflammation of the gallbladder is suspected further studies are needed.
  • Hepatitis/Elevated liver enzymes/Jaundice
  • Diabetic retinopathy problems: Changes in vision in those with type II diabetes, particularly vision problems may worsen in those with a history of diabetic retinopathy
  • Severe gastrointestinal disease - may cause gastrointestinal disease; do not use if you have a history of severe gastrointestinal disease
  • Signs of low blood sugar (for example, dizziness, weakness, shakiness, jitteriness, headache, anxiety/mood changes, rapid heartbeat, confusion, slurred speech, sweating, or lightheadedness). While this is rare with GLP-1s, if it occurs, please seek in-person care immediately. If you have these symptoms, try having liquid or food containing sugar (around 15-20 grams) —drinking juice, having regular soda, or eating some hard candies right away, as this will help raise your blood sugar quickly. If taken with insulin or an insulin secretagogue (i.e. sulfonylurea such as Glipizide, glimepiride, and glyburide) it is best to talk to your healthcare provider about possibly lowering the dose of these medications to lower the risk of hypoglycemia.
  • Increasing heart rate
  • Worsening depression, behavior changes, or suicidality

Never share the semaglutide with other people

Drug Interactions

As with other medications, compounded semaglutide can interact with alcohol and certain prescription and non-prescription medications and herbal products. The risk of hypoglycemia is increased when combined with insulin or insulin secretagogues such as sulfonylureas. Compounded semaglutide delays gastric emptying and may impact the absorption of oral medications. If you are on papillary hormone medication, prior to starting compounded semaglutide, please review the timing of taking your papillary hormone medication with the doctor who prescribes it as it may need to be adjusted. The drug levels of medications with narrow therapeutic windows (ie warfarin) should be monitored closely while on compounded semaglutide.

Please consult the pharmaceutical packaging for a full list of side effects, warnings, interactions and additional information.

To report suspected adverse reactions to compounded semaglutide, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

In case of emergencies, please call 911 or go to the nearest emergency room.

Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

BLACK BOX WARNING

GLP-1s are contraindicated in individuals with a history of medullary thyroid carcinoma, a family history of such, or in patients with multiple endocrine neoplasia syndrome type 2. Do not take them if you have ever had thyroid cancer. In studies with rodents, GLP-1s caused thyroid tumors, including thyroid cancer; it is not known if they will cause thyroid tumors or cancer in humans. Please notify your doctor ASAP if you develop trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath.

If you experience a medical emergency, call 911 or go to the nearest emergency room.

Tell your healthcare provider about your medical history prior to taking semaglutide.

Avoid alcohol while taking this medication. If you’re taking diabetes medications, please discuss this with your prescribing doctor before starting semaglutide, as your diabetes medications may need to be adjusted as you lose weight.

Use adequate contraception while taking this medication. Do not take this medication if pregnant, trying to get pregnant or breastfeeding. If you plan to become pregnant, this medication needs to be stopped at least 2 months before trying. This medication may cause fetal harm.

Notify your doctor if you have kidney, liver, or pancreas problems.

Stop using semaglutide and call your healthcare provider immediately if you have severe stomach or abdomen pain that will not go away, with or without vomiting.

Stop using semaglutide and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat.

Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue semaglutide if suspected and promptly seek medical advice.

MIC+B12

Safety Information:

Side effects are typically mild and go away over time.

Common side effects:

  • Discomfort or redness at the injection area
  • Skin itching or sensations of overall swelling  
  • Muscular cramps and weakness
  • Nausea and issues with urination
  • Swelling around the ankles or feet  
  • Excessive fatigue

Precautions:

  • Avoid using B12/MIC if you are pregnant, nursing, or if you are planning to become pregnant or to breastfeed.
  • Should itching/irritation persist, consider using an over-the-counter anti-itch cream containing hydrocortisone, or stop using the product altogether.
  • In the uncommon event of more severe reactions, such as an irregular heartbeat or difficulty breathing, cease usage immediately and consult your healthcare provider.

Note: The statements above have not been reviewed by the Food and Drug Administration. This product is not designed to diagnose, treat, cure, or prevent any condition.

Compounded Semaglutide

*Compounded medications may be prescribed by physicians but have not been FDA regulated for safety, effectiveness, or quality. FDA-approved medicines containing semaglutide are available.

WARNING

Please contact your doctor ASAP and seek in-person care immediately if a side effect becomes problematic or you experience:

  • Severe nausea and/or vomiting resulting in dehydration—it is important to stay well hydrated and drink plenty of fluids while on this medication
    Kidney problems/kidney failure - vomiting, nausea, diarrhea can cause dehydration and kidney issues and make kidney problems worse in individuals who have pre-existing kidney conditions; may sometimes lead to the need for hemodialysis
  • Thyroid C-Cell Tumor: Trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath (see black box warning below)
  • Pancreatitis: Severe pain in your abdomen or back that will not go away
  • Acute gallbladder disease - Pain in the middle or right upper stomach, fever, white parts of your eyes turn yellow or skin turns yellow, nausea/vomiting. If gallstones or inflammation of the gallbladder is suspected further studies are needed.
  • Hepatitis/Elevated liver enzymes/Jaundice
  • Diabetic retinopathy problems: Changes in vision in those with type II diabetes, particularly vision problems may worsen in those with a history of diabetic retinopathy
  • Severe gastrointestinal disease - may cause gastrointestinal disease; do not use if you have a history of severe gastrointestinal disease
  • Signs of low blood sugar (for example, dizziness, weakness, shakiness, jitteriness, headache, anxiety/mood changes, rapid heartbeat, confusion, slurred speech, sweating, or lightheadedness). While this is rare with GLP-1s, if it occurs, please seek in-person care immediately. If you have these symptoms, try having liquid or food containing sugar (around 15-20 grams) —drinking juice, having regular soda, or eating some hard candies right away, as this will help raise your blood sugar quickly. If taken with insulin or an insulin secretagogue (i.e. sulfonylurea such as Glipizide, glimepiride, and glyburide) it is best to talk to your healthcare provider about possibly lowering the dose of these medications to lower the risk of hypoglycemia.
  • Increasing heart rate
  • Worsening depression, behavior changes, or suicidality

Never share the semaglutide with other people

Drug Interactions

As with other medications, compounded semaglutide can interact with alcohol and certain prescription and non-prescription medications and herbal products. The risk of hypoglycemia is increased when combined with insulin or insulin secretagogues such as sulfonylureas. Compounded semaglutide delays gastric emptying and may impact the absorption of oral medications. If you are on papillary hormone medication, prior to starting compounded semaglutide, please review the timing of taking your papillary hormone medication with the doctor who prescribes it as it may need to be adjusted. The drug levels of medications with narrow therapeutic windows (ie warfarin) should be monitored closely while on compounded semaglutide.

Please consult the pharmaceutical packaging for a full list of side effects, warnings, interactions and additional information.

To report suspected adverse reactions to compounded semaglutide, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

In case of emergencies, please call 911 or go to the nearest emergency room.

Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

BLACK BOX WARNING

GLP-1s are contraindicated in individuals with a history of medullary thyroid carcinoma, a family history of such, or in patients with multiple endocrine neoplasia syndrome type 2. Do not take them if you have ever had thyroid cancer. In studies with rodents, GLP-1s caused thyroid tumors, including thyroid cancer; it is not known if they will cause thyroid tumors or cancer in humans. Please notify your doctor ASAP if you develop trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath.

If you experience a medical emergency, call 911 or go to the nearest emergency room.

Tell your healthcare provider about your medical history prior to taking semaglutide.

Avoid alcohol while taking this medication. If you’re taking diabetes medications, please discuss this with your prescribing doctor before starting semaglutide, as your diabetes medications may need to be adjusted as you lose weight.

Use adequate contraception while taking this medication. Do not take this medication if pregnant, trying to get pregnant or breastfeeding. If you plan to become pregnant, this medication needs to be stopped at least 2 months before trying. This medication may cause fetal harm.

Notify your doctor if you have kidney, liver, or pancreas problems.

Stop using semaglutide and call your healthcare provider immediately if you have severe stomach or abdomen pain that will not go away, with or without vomiting.

Stop using semaglutide and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat.

Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue semaglutide if suspected and promptly seek medical advice.

MIC+B12

Safety Information:

Side effects are typically mild and go away over time.

Common side effects:

  • Discomfort or redness at the injection area
  • Skin itching or sensations of overall swelling  
  • Muscular cramps and weakness
  • Nausea and issues with urination
  • Swelling around the ankles or feet  
  • Excessive fatigue

Precautions:

  • Avoid using B12/MIC if you are pregnant, nursing, or if you are planning to become pregnant or to breastfeed.
  • Should itching/irritation persist, consider using an over-the-counter anti-itch cream containing hydrocortisone, or stop using the product altogether.
  • In the uncommon event of more severe reactions, such as an irregular heartbeat or difficulty breathing, cease usage immediately and consult your healthcare provider.

Note: The statements above have not been reviewed by the Food and Drug Administration. This product is not designed to diagnose, treat, cure, or prevent any condition.

Methylene Blue

BLACK BOX WARNING

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS Methylene blue may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs.

  • Serotonin Syndrome Risk:
    • Mechanism: Methylene blue can inhibit the enzyme monoamine oxidase A (MAO-A), which is responsible for breaking down serotonin. In patients taking medications that increase serotonin levels (such as
      SSRIs, SNRIs, MAOIs, tricyclic antidepressants, and other serotonergic drugs), the additional inhibition of serotonin metabolism by methylene blue can lead to serotonin syndrome.
    • Symptoms of serotonin syndrome:
      • Agitation or restlessness
      • Confusion
      • Rapid heart rate
      • High blood pressure
      • Dilated pupils
      • Loss of muscle coordination or twitching muscles
      • Muscle rigidity
      • Heavy sweating
      • Diarrhea, nausea, or vomiting
      • Severe cases may lead to high fever, seizures, or loss of consciousness.
  • Contraindications:
    • Methylene blue is contraindicated in patients who are on serotonergic drugs unless it is an emergency situation where the benefits outweigh the risks, and proper monitoring for serotonin syndrome can be done.
  • Special Considerations:
    • It is advised to discontinue serotonergic medications 2 weeks before dministering methylene blue if possible, and monitoring is essential if it must be given.

This black box warning is critical to ensure patient safety, particularly in avoiding life-threatening serotonin syndrome in vulnerable populations.

Common side effects:

The side effects of low-dose methylene blue are generally mild, but can include several notable adverse reactions.

  • Headache
  • Blue/green urine or other bodily secretions
  • Hhypokalemia (lowpotassium levels)
  • Diarrhea
  • Hypomagnesemia (low magnesium levels)
  • Myoclonus (sudden, brief, involuntary muscle contractions/jerks)
  • Nausea
  • Seizure-like phenomena.

Other potential side effects include hemolytic anemia, particularly in individuals with G6PD deficiency, and various gastrointestinal and respiratory symptoms such as abdominal pain, dry mouth, and nasal congestion. Additionally, methylene blue can interfere with in-vivo monitoring devices and laboratory tests, which is an important consideration for patients undergoing regular medical evaluations

Contraindications:

Do not use methylene blue if you have G6PD deficiency, or if you use of SSRIs, SNRIs, MAOIs, or ADHD stimulants. You should also avoid this medication if you have hypersensitivity to methylene blue or its components.

Storage:

Regular monitoring of serotonin levels is required for patients on certain antidepressants. Patients should also avoid excessive exposure to light, as methylene blue is photosensitizing.

Precautions:

Store in a cool, dry place away from direct sunlight. Do not freeze.

Note: The statements above have not been reviewed by the Food and Drug Administration. This product is not designed to diagnose, treat, cure, or prevent any condition.

Vardenafil+Tadalafil

Common side effects:

  • Headache
  • Flushing
  • Nasal Congestion
  • Indigestion
  • Back Pain (more common with tadalafil)
  • Muscle Aches
  • Visual Disturbances (blurred vision, changes in color vision)

More serious, but less common side effects:

  • Hypotension: A significant drop in blood pressure, especially when combined with nitrates or certain other medications.
  • Cardiovascular Events: Risk of heart attack, stroke, or arrhythmias, particularly in individuals with pre-existing heart conditions.
  • Priapism: Prolonged erection lasting more than 4 hours, requiring medical attention.
  • Hearing Loss: Sudden decrease or loss of hearing.
  • Vision Loss: Rare cases of non-arteritic anterior ischemic optic neuropathy (NAION).

See an all inclusive list of side effects from Mayo Clinic.

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Monitoring Plan

To ensure your safety and the effectiveness of the treatment, regular monitoring will be required, including:

  • Baseline Testing:
    • Evaluation of current medications to assess for potential drug interactions.
  • Ongoing Monitoring:
    • Periodic assessments for side effects or adverse reactions.
  • Symptom Assessment:
    • Monitoring for any cardiovascular symptoms during exercise.
    • Reporting any visual or hearing changes immediately.
  • Follow-Up Visits:
    • Scheduled appointments to discuss your progress and address any concerns.

Contraindications:

Do not use Vardenafil or Tadalafil with nitrate medications, as this can cause a dangerous drop in blood pressure.  Do not use with other ED medications. Avoid use if you have serious heart conditions. Avoid use with NO boosters (separate use by at least 2 hours).

Precautions:

Consult your healthcare provider if you have cardiovascular disease, liver or kidney dysfunction, or a history of stroke.

Note: The statements above have not been reviewed by the Food and Drug Administration. This product is not designed to diagnose, treat, cure, or prevent any condition.

MIC+B12

Safety Information:

Side effects are typically mild and go away over time.

Common side effects:

  • Discomfort or redness at the injection area
  • Skin itching or sensations of overall swelling  
  • Muscular cramps and weakness
  • Nausea and issues with urination
  • Swelling around the ankles or feet  
  • Excessive fatigue

Precautions:

  • Avoid using B12/MIC if you are pregnant, nursing, or if you are planning to become pregnant or to breastfeed.
  • Should itching/irritation persist, consider using an over-the-counter anti-itch cream containing hydrocortisone, or stop using the product altogether.
  • In the uncommon event of more severe reactions, such as an irregular heartbeat or difficulty breathing, cease usage immediately and consult your healthcare provider.

Note: The statements above have not been reviewed by the Food and Drug Administration. This product is not designed to diagnose, treat, cure, or prevent any condition.

Sermorelin

Safety Information:

Side effects are typically mild and go away over time.

Common side effects:

  • Pain, redness, or swelling at the place of injection

Rare side effects:

  • Itching
  • Trouble swallowing
  • Dizziness
  • Flushing
  • Headache
  • Sleepiness
  • Trouble sitting still

You shouldn't use Sermorelin if:

  • You have hypersensitivity to Sermorelin or any of its ingredients
  • You're pregnant
  • You're breastfeeding
  • You have active cancer

Precautions:

Regular monitoring of growth hormone levels, blood sugar levels, and overall health by a healthcare provider is recommended.

Note: The statements above have not been reviewed by the Food and Drug Administration. This product is not designed to diagnose, treat, cure, or prevent any condition.

Everyday+

Safety Information

Side effects are typically mild and go away over time during the first 3 to 5 days.

What are the most common side effects?

  • Nausea
  • Vomiting
  • Decreased appetite
  • Dizziness
  • Headache
  • Diarrhea
  • Gastritis
  • Bloated feeling or passing gas
  • Stomach pain
  • Oily stools
  • Loss of bowel control
  • (see full list below)

Side Effect Profiles

Acarbose safety information and drug interactions: 
Mayo Clinic
|| National Institutes of Health

Unlike sulfonylureas, this group of drugs does not cause hypoglycemia. However, combination therapy with sulfonylureas or insulin poses the risk of hypoglycemia; in that case, the patient should understand the need to keep glucose with them. 

Orlistat

  • back pain
  • difficulty with moving
  • gas with leaky bowel movements
  • inability to hold bowel movement
  • increases in bowel movements
  • loss of bowel control
  • oily bowel movements
  • oily spotting of underclothes
  • stomach pain or discomfort

See a complete list of Orlistat side effects here.

Special Considerations

Low Dose Naltrexone

You must stop taking low dose naltrexone at least 48 hours prior to any procedure that requires sedation. Ensure that your doctor knows that you are taking LDN prior to the procedure. It is recommended not to resume taking LDN until 48 hour after your last dose of medication that was 

prescribed for the procedure.It is important to notify your doctor if you are taking any thyroid medication. LDN may impact your thyroid levels. Stop taking LDN and notify your prescriber if you have any signs or symptoms of hyperthyroidism such as excess sweating,  fast heart rate, hyperactivity, issues with sleeping, or restlessness.

Orlistat

Because orlistat may decrease the amount of some vitamins that your body absorbs from food, you will need to take a multivitamin supplement once a day. Take the vitamin supplement at least 2 hours before or after taking orlistat. 

You may also take your multivitamin supplement at bedtime.

When using orlistat, your diet should contain no more than 30% of calories as fat. More fat in your diet will increase the side effects of this medicine. Your diet should be nutritionally balanced, and your daily intake of fat, carbohydrates, and protein should be distributed over three main meals.

Carefully follow your doctor's instructions for a reduced-calorie diet plan and regular exercise. Talk with your doctor before starting any exercise program.

For a full list of side effects, interactions, and other safety information click here

Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Compounded Semaglutide + B12

*Compounded medications may be prescribed by physicians but have not been FDA regulated for safety, effectiveness, or quality. FDA-approved medicines containing semaglutide are available.

WARNING

Please contact your doctor ASAP and seek in-person care immediately if a side effect becomes problematic or you experience:

  • Severe nausea and/or vomiting resulting in dehydration—it is important to stay well hydrated and drink plenty of fluids while on this medication
  • Kidney problems/kidney failure - vomiting, nausea, diarrhea can cause dehydration and kidney issues and make kidney problems worse in individuals who have pre-existing kidney conditions; may sometimes lead to the need for hemodialysis
    papillary C-Cell Tumor: Trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath (see black box warning below)
  • Pancreatitis: Severe pain in your abdomen or back that will not go away
  • Acute gallbladder disease - Pain in the middle or right upper stomach, fever, white parts of your eyes turn yellow or skin turns yellow, nausea/vomiting. If gallstones or inflammation of the gallbladder is suspected further studies are needed.
  • Hepatitis/Elevated liver enzymes/Jaundice
  • Diabetic retinopathy problems: Changes in vision in those with type II diabetes, particularly vision problems may worsen in those with a history of diabetic retinopathy
  • Severe gastrointestinal disease - may cause gastrointestinal disease; do not use if you have a history of severe gastrointestinal disease
  • Signs of low blood sugar (for example, dizziness, weakness, shakiness, jitteriness, headache, anxiety/mood changes, rapid heartbeat, confusion, slurred speech, sweating, or lightheadedness). While this is rare with GLP-1s, if it occurs, please seek in-person care immediately. If you have these symptoms, try having liquid or food containing sugar (around 15-20 grams) —drinking juice, having regular soda, or eating some hard candies right away, as this will help raise your blood sugar quickly. If taken with insulin or an insulin secretagogue (i.e. sulfonylurea such as Glipizide, glimepiride, and glyburide) it is best to talk to your healthcare provider about possibly lowering the dose of these medications to lower the risk of hypoglycemia.
  • Increasing heart rate
  • Worsening depression, behavior changes, or suicidality

Never share the semaglutide with other people

DRUG INTERACTIONS

As with other medications, compounded semaglutide can interact with alcohol and certain prescription and non-prescription medications and herbal products. The risk of hypoglycemia is increased when combined with insulin or insulin secretagogues such as sulfonylureas. Compounded semaglutide delays gastric emptying and may impact the absorption of oral medications. If you are on papillary hormone medication, prior to starting compounded semaglutide, please review the timing of taking your papillary hormone medication with the doctor who prescribes it as it may need to be adjusted. The drug levels of medications with narrow therapeutic windows (ie warfarin) should be monitored closely while on compounded semaglutide.

Please consult the pharmaceutical packaging for a full list of side effects, warnings, interactions and additional information.

To report suspected adverse reactions to compounded semaglutide, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

In case of emergencies, please call 911 or go to the nearest emergency room.

Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Oral Semaglutide GLP-1

*Compounded medications may be prescribed by physicians but have not been FDA regulated for safety, effectiveness, or quality. FDA-approved medicines containing semaglutide are available.

WARNING

Please contact your doctor ASAP and seek in-person care immediately if a side effect becomes problematic or you experience:

  • Severe nausea and/or vomiting resulting in dehydration -  it is important to stay well hydrated and drink plenty of fluids while on this medication.
  • Kidney problems/kidney failure - vomiting, nausea, diarrhea can cause dehydration and kidney issues and make kidney problems worse in individuals who have pre-existing kidney conditions; may sometimes lead to the need for hemodialysis.
  • C-Cell Tumor: Trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath (see black box warning below).
  • Pancreatitis: Severe pain in your abdomen or back that will not go away.
  • Acute gallbladder disease - Pain in the middle or right upper stomach, fever, white parts of your eyes turn yellow or skin turns yellow, nausea/vomiting. If gallstones or inflammation of the gallbladder is suspected further studies are needed.
  • Hepatitis/Elevated liver enzymes/Jaundice
  • Diabetic retinopathy problems: Changes in vision in those with type II diabetes, particularly vision problems may worsen in those with a history of diabetic retinopathy.
  • Severe gastrointestinal disease - may cause gastrointestinal disease; do not use if you have a history of severe gastrointestinal disease
  • Signs of low blood sugar (for example, dizziness, weakness, shakiness, jitteriness, headache, anxiety/mood changes, rapid heartbeat, confusion, slurred speech, sweating, or lightheadedness). While this is rare with GLP-1s, if it occurs, please seek in-person care immediately. If you have these symptoms, try having liquid or food containing sugar (around 15-20 grams) —drinking juice, having regular soda, or eating some hard candies right away, as this will help raise your blood sugar quickly. If taken with insulin or an insulin secretagogue (i.e. sulfonylurea such as Glipizide, glimepiride, and glyburide) it is best to talk to your healthcare provider about possibly lowering the dose of these medications to lower the risk of hypoglycemia.
  • Increasing heart rate
  • Worsening depression, behavior changes, or suicidality
  • Never share the semaglutide with other people

Drug Interactions

As with other medications, oral semaglutide can interact with alcohol and certain prescription and non-prescription medications and herbal products. The risk of hypoglycemia is increased when combined with insulin or insulin secretagogues such as sulfonylureas. Oral semaglutide delays gastric emptying and may impact the absorption of oral medications. If you are on hormone medication, prior to starting oral semaglutide, please review the timing of taking your hormone medication with the doctor who prescribes it as it may need to be adjusted. The drug levels of medications with narrow therapeutic windows (ie warfarin) should be monitored closely while on oral semaglutide.

Please consult the pharmaceutical packaging for a full list of side effects, warnings, interactions and additional information.

To report suspected adverse reactions to o semaglutide, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

In case of emergencies, please call 911 or go to the nearest emergency room.

Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Everyday+

Safety Information

Side effects are typically mild and go away over time.

What are the most common side effects?

  • Nausea
  • Vomiting
  • Decreased appetite
  • Dizziness
  • Headache
  • Diarrhea
  • Gastritis

Full side effect profile:

  • Low dose Naltrexone: nausea/vomiting, decreased appetite. Dizziness, headache, insomnia (can resolve in 2 weeks), vivid dreams, joint pain, muscle cramps, tooth pain, and anxiety which are all more commonly seen at higher doses.
  • Inositol: nausea, vomiting, diarrhea, abdominal pain/cramps, gastritis, dizziness, high BP, decreases absorption of Iron, Ca, and Zn in bloodstream, hypoglycemia—all usually mild and go away over time. All typically seen at higher doses of 1,000-4,000mg per day.
  • L-Carnitine: nausea, vomiting, diarrhea, abdominal pain/cramps, gastritis, body odor—all usually mild and go away over time. All typically seen at higher doses of 1,000-3,000mg per day. At high doses (1,000mg-3000mg) L-Carnitine may affect the efficacy of warfarin or dicumarol.

Wegovy®

BLACK BOX WARNING:

GLP-1s are contraindicated in individuals with a history of medullary papillary carcinoma, a family history of such, or in patients with multiple endocrine neoplasia syndrome type 2. Do not take them if you have ever had papillary cancer. In studies with rodents, GLP-1s caused papillary tumors, including papillary cancer; it is not known if they will cause papillary tumors or cancer in humans. Please notify your doctor ASAP if you develop trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath.

If you experience a medical emergency, call 911 or go to the nearest emergency room.

Tell your healthcare provider about your medical history prior to taking Wegovy®.

Avoid alcohol while taking this medication. If you’re taking diabetes medications, please discuss this with your prescribing doctor before starting Wegovy®, as your diabetes medications may need to be adjusted as you lose weight.

Use adequate contraception while taking this medication. Do not take this medication if pregnant, trying to get pregnant or breastfeeding. If you plan to become pregnant, this medication needs to be stopped at least 2 months before trying. This medication may cause fetal harm.

Notify your doctor if you have kidney, liver, or pancreas problems.

Stop using Wegovy® and call your healthcare provider immediately if you have severe stomach or abdomen pain that will not go away, with or without vomiting.

Stop using Wegovy® and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat.

Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue Wegovy® if suspected and promptly seek medical advice.

WARNING

Please contact your doctor ASAP and seek in-person care immediately if a side effect becomes problematic or you experience:

  • Severe nausea and/or vomiting resulting in dehydration-  it is important to stay well hydrated and drink plenty of fluids while on this medication
  • Kidney problems/kidney failure - vomiting, nausea, diarrhea can cause dehydration and kidney issues and make kidney problems worse in individuals who have pre-existing kidney conditions; may sometimes lead to the need for hemodialysis
  • papillary C-Cell Tumor: Trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath (see black box warning below)
  • Pancreatitis: Severe pain in your abdomen or back that will not go away
  • Acute gallbladder disease - Pain in the middle or right upper stomach, fever, white parts of your eyes turn yellow or skin turns yellow, nausea/vomiting. If gallstones or inflammation of the gallbladder is suspected further studies are needed.
  • Hepatitis/Elevated liver enzymes/Jaundice
  • Diabetic retinopathy problems: Changes in vision in those with type II diabetes, particularly vision problems may worsen in those with a history of diabetic retinopathy
  • Severe gastrointestinal disease - may cause gastrointestinal disease; do not use if you have a history of severe gastrointestinal disease
  • Signs of low blood sugar (for example, dizziness, weakness, shakiness, jitteriness, headache, anxiety/mood changes, rapid heartbeat, confusion, slurred speech, sweating, or lightheadedness). While this is rare with GLP-1s, if it occurs, please seek in-person care immediately. If you have these symptoms, try having liquid or food containing sugar (around 15-20 grams) —drinking juice, having regular soda, or eating some hard candies right away, as this will help raise your blood sugar quickly. If taken with insulin or an insulin secretagogue (i.e. sulfonylurea such as Glipizide, glimepiride, and glyburide) it is best to talk to your healthcare provider about possibly lowering the dose of these medications to lower the risk of hypoglycemia.
  • Increasing heart rate
  • Worsening depression, behavior changes, or suicidality
  • Never share the Wegovy® pen with other people

SIDE EFFECTS

Many people experience no side effects. Some of the most common or potential side effects include:

  • Nausea
  • Constipation
  • Vomiting
  • Diarrhea
  • Abdominal Pain
  • Headache
  • Indigestion
  • Injection site reactions
  • Dizziness
  • Back pain
  • Increased Lipase or Amylase
  • Altered taste
  • Nasopharyngitis (common cold)
  • Passing Gas
  • Bloating
  • Belching
  • Gastroenteritis
  • Decreased appetite
  • Fatigue
  • Gastroesophageal reflux disease
  • Low blood sugar (hypoglycemia) in those with type II diabetes
  • Upset stomach

These symptoms often subside as your body adjusts to the medications. Please notify your provider if side effects persist. For a complete list of side effects, review the medication packaging inserts.

DRUG INTERACTIONS

As with other medications, Wegovy® can interact with alcohol and certain prescription and non-prescription medications and herbal products. The risk of hypoglycemia is increased when combined with insulin or insulin secretagogues such as sulfonylureas. Wegovy® delays gastric emptying and may impact the absorption of oral medications. If you are on papillary hormone medication, prior to starting Wegovy®, please review the timing of taking your papillary hormone medication with the doctor who prescribes it as it may need to be adjusted. The drug levels of medications with narrow therapeutic windows (ie warfarin) should be monitored closely while on Wegovy®.

Please consult the pharmaceutical packaging for a full list of side effects, warnings, interactions and additional information.

To report suspected adverse reactions to Wegovy® contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

In case of emergencies, please call 911 or go to the nearest emergency room.

Ozempic®

BLACK BOX WARNING:

GLP-1s are contraindicated in individuals with a history of medullary thyroid carcinoma, a family history of such, or in patients with multiple endocrine neoplasia syndrome type 2. Do not take them if you have ever had thyroid cancer. In studies with rodents, GLP-1s caused thyroid tumors, including thyroid cancer; it is not known if they will cause thyroid tumors or cancer in humans. Please notify your doctor ASAP if you develop trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath.

If you experience a medical emergency, call 911 or go to the nearest emergency room.

Tell your healthcare provider about your medical history prior to taking Ozempic®.

Avoid alcohol while taking this medication. If you’re taking diabetes medications, please discuss this with your prescribing doctor before starting Ozempic®, as your diabetes medications may need to be adjusted as you lose weight.

Use adequate contraception while taking this medication. Do not take this medication if pregnant, trying to get pregnant or breastfeeding. If you plan to become pregnant, this medication needs to be stopped at least 2 months before trying. This medication may cause fetal harm.

Notify your doctor if you have kidney, liver, or pancreas problems.

Stop using Ozempic® and call your healthcare provider immediately if you have severe stomach or abdomen pain that will not go away, with or without vomiting.

Stop using Ozempic® and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat.

Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue Ozempic® if suspected and promptly seek medical advice.

WARNING

Please contact your doctor ASAP and seek in-person care immediately if a side effect becomes problematic or you experience:

  • Severe nausea and/or vomiting resulting in dehydration-  it is important to stay well hydrated and drink plenty of fluids while on this medication
  • Kidney problems/kidney failure - vomiting, nausea, diarrhea can cause dehydration and kidney issues and make kidney problems worse in individuals who have pre-existing kidney conditions; may sometimes lead to the need for hemodialysis
  • thyroid C-Cell Tumor: Trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath (see black box warning below)
  • Pancreatitis: Severe pain in your abdomen or back that will not go away
  • Acute gallbladder disease - Pain in the middle or right upper stomach, fever, white parts of your eyes turn yellow or skin turns yellow, nausea/vomiting. If gallstones or inflammation of the gallbladder is suspected further studies are needed.
  • Hepatitis/Elevated liver enzymes/Jaundice
  • Diabetic retinopathy problems: Changes in vision in those with type II diabetes, particularly vision problems may worsen in those with a history of diabetic retinopathy
  • Severe gastrointestinal disease - may cause gastrointestinal disease; do not use if you have a history of severe gastrointestinal disease
  • Signs of low blood sugar (for example, dizziness, weakness, shakiness, jitteriness, headache, anxiety/mood changes, rapid heartbeat, confusion, slurred speech, sweating, or lightheadedness). While this is rare with GLP-1s, if it occurs, please seek in-person care immediately. If you have these symptoms, try having liquid or food containing sugar (around 15-20 grams) —drinking juice, having regular soda, or eating some hard candies right away, as this will help raise your blood sugar quickly. If taken with insulin or an insulin secretagogue (ie sulfonylurea) it is best to talk to your healthcare provider about possibly lowering the dose of these medications to lower the risk of hypoglycemia.
  • Increasing heart rate
  • Worsening depression, behavior changes, or suicidality
  • Never share the Ozempic® pen with other people

SIDE EFFECTS

Many people experience no side effects. Some of the most common or potential side effects include:

  • Nausea
  • Constipation
  • Vomiting
  • Diarrhea
  • Abdominal Pain
  • Headache
  • Indigestion
  • Injection site reactions
  • Dizziness
  • Back pain
  • Increased Lipase or Amylase
  • Altered taste
  • Nasopharyngitis (common cold)
  • Passing Gas
  • Bloating
  • Belching
  • Gastroenteritis
  • Decreased appetite
  • Fatigue
  • Gastroesophageal reflux disease
  • Low blood sugar (hypoglycemia) in those with type II diabetes
  • Upset stomach

These symptoms often subside as your body adjusts to the medications. Please notify your provider if side effects persist. For a complete list of side effects, review the medication packaging inserts.

DRUG INTERACTIONS

As with other medications, Ozempic® can interact with alcohol and certain prescription and non-prescription medications and herbal products. The risk of hypoglycemia is increased when combined with insulin or insulin secretagogues such as sulfonylureas. Ozempic® delays gastric emptying and may impact the absorption of oral medications. If you are on thyroid hormone medication, prior to starting Ozempic®, please review the timing of taking your thyroid hormone medication with the doctor who prescribes it as it may need to be adjusted. The drug levels of medications with narrow therapeutic windows (ie warfarin) should be monitored closely while on Ozempic®.

Please consult the pharmaceutical packaging for a full list of side effects, warnings, interactions and additional information.

To report suspected adverse reactions to Ozempic® contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

In case of emergencies, please call 911 or go to the nearest emergency room.

Compounded Tirzepatide

*Compounded medications may be prescribed by physicians but have not been FDA regulated for safety, effectiveness, or quality. FDA-approved medicines containing trizepatide are available.

WARNING

Compounded tirzepatide usage has been associated with the potential development of thyroid tumors, including thyroid cancer. Watch for any potential symptoms, such as neck lumps or swelling, hoarseness, difficulty swallowing, or breathlessness. Should any of these symptoms arise, it is imperative to inform your healthcare provider promptly.

Avoid using compounded tirzepatide if you or any family members have a history of medullary thyroid carcinoma (MTC), a specific type of thyroid cancer. Similarly, refrain from its use if diagnosed with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you've previously experienced a severe allergic reaction to tirzepatide or any of its components.

Serious Side Effects

Compounded tirzepatide carries the risk of severe side effects, which include:

  • Gastrointestinal Issues: Reports indicate the possibility of severe stomach problems associated with compounded tirzepatide usage. Notify your healthcare provider if you experience persistent or severe stomach discomfort.
  • Kidney Complications: Diarrhea, nausea, and vomiting may lead to dehydration, potentially resulting in kidney problems. Adequate fluid intake is crucial to mitigate this risk.
  • Gallbladder Concerns: Some individuals may encounter gallbladder problems while using compounded tirzepatide. Seek immediate medical attention if symptoms such as upper abdominal pain, fever, jaundice, or changes in stool color occur.
  • Pancreatitis: Discontinue use and contact your healthcare provider if you experience persistent abdominal pain, with or without vomiting, as it could indicate inflammation of the pancreas.
  • Allergic Reactions: Cease compounded tirzepatide usage and seek urgent medical assistance if you develop symptoms of a severe allergic reaction, including facial swelling, breathing difficulties, rash, or rapid heartbeat.
  • Hypoglycemia: The risk of low blood sugar may increase when using compounded tirzepatide alongside medications that lower blood sugar levels. Recognizable symptoms include dizziness, sweating, confusion, and rapid heartbeat.
  • Vision Changes: Notify your healthcare provider of any alterations in vision observed during tirzepatide treatment.
  • Depression or Suicidal Thoughts: Pay close attention to changes in mood or mental state while using tirzepatide, and promptly report any concerns to your healthcare provider.

Common Side Effects

The most frequently reported side effects of compounded tirzepatide include:

  • Nausea
  • Diarrhea
  • Vomiting
  • Constipation
  • Abdominal pain
  • Indigestion
  • Injection site reactions
  • Fatigue
  • Allergic reactions
  • Belching
  • Hair loss
  • Heartburn

These side effects are not exhaustive. Should you experience any persistent or bothersome side effects, discuss them with your healthcare provider for appropriate management.

Tell your healthcare provider if you have any side effects.

To report suspected severe side effects or adverse reactions to compounded trizepatide, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. In case of emergencies, please call 911 or go to the nearest emergency room.

Drug Interactions

As with other medications, compounded trizepatide can interact with alcohol and certain prescription and non-prescription medications and herbal products. The risk of hypoglycemia is increased when combined with insulin or insulin secretagogues such as sulfonylureas. Compounded trizepatide delays gastric emptying and may impact the absorption of oral medications. If you are on papillary hormone medication, prior to starting compounded trizepatide, please review the timing of taking your papillary hormone medication with the doctor who prescribes it as it may need to be adjusted. The drug levels of medications with narrow therapeutic windows (ie warfarin) should be monitored closely while on compounded trizepatide.

Please consult the pharmaceutical packaging for a full list of side effects, warnings, interactions and additional information.

Tirzepatide may alter the efficacy of birth control pills. Talk with your doctor before starting tirzepatide if you are on birth control. Your healthcare provider may recommend another type of birth control for 4 weeks after you start tirzepatide and for 4 weeks after each increase in your dose.

Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Mounjaro®

Safety Information

Do not use if you have been diagnosed with the following:

  • Diabetic ketoacidosis
  • Type 1 diabetes
  • Diabetic retinopathy
  • Kidney disease
  • Multiple endocrine neoplasia syndrome type 2 (MEN 2)
  • Thyroid cancer
  • Pancreatitis

Some side effects may occur that do not require medical attention, as they may lessen as your body adjusts to the medication. You may experience more gastrointestinal (GI) side effects when you increase your dose, however it should be less over time. Reach out to your healthcare provider if you experience any unwanted side effects as there may be ways to prevent or reduce side effects. You may always reach out with any additional questions regarding your medication therapy and side effects.

More common side effects:

  • acid or sour stomach
  • belching
  • constipation
  • diarrhea
  • stomach discomfort or upset
  • stomach pain
  • hypoglycemia (low blood sugar)
  • injection-site reactions
  • gallbladder disease
  • hypersensitivity reactions

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

For a full list of side effects: https://www.mayoclinic.org/drugs-supplements/tirzepatide-subcutaneous-route/side-effects/drg-20534045?p=1

Mounjaro® Safety Information

Mounjaro® (mown-JAHR-OH) is an injectable medicine for adults with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose).

  • It is not known if Mounjaro can be used in people who have had inflammation of the pancreas (pancreatitis). Mounjaro is not for use in people with type 1 diabetes. It is not known if Mounjaro is safe and effective for use in children under 18 years of age.

Warnings

Mounjaro® may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

  • Do not use Mounjaro if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).
  • Do not use Mounjaro if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Do not use Mounjaro if you are allergic to it or any of the ingredients in Mounjaro.

Mounjaro® may cause serious side effects, including:

  • Inflammation of the pancreas (pancreatitis). Stop using Mounjaro and call your healthcare provider right away if you have severe painin your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back.
  • Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Mounjaro with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, or mood changes, hunger, weakness and feeling jittery.
  • Serious allergic reactions. Stop using Mounjaro and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, and very rapid heartbeat.
  • Kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomitingmay cause a loss of fluids (dehydration), which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration.
  • Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Mounjaro. Tell your healthcare provider if you have stomach problems that are severe or will not go away.
  • Changes in vision. Tell your healthcare provider if you have changes in vision during treatment with Mounjaro.
  • Gallbladder problems. Gallbladder problems have happened in some people who use Mounjaro. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), and clay-colored stools.

Common side effects

The most common side effects of Mounjaro® include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach (abdominal) pain. These are not all the possible side effects of Mounjaro. Talk to your healthcare provider about any side effect that bothers you or doesn’t go away.

Tell your healthcare provider if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before using Mounjaro®

  • Your healthcare provider should show you how to use Mounjaro before you use it for the first time.
  • Talk to your healthcare provider about low blood sugar and how to manage it.
  • If you take birth control pills by mouth, talk to your healthcare provider before youuse Mounjaro. Birth control pills may not work as well while using Mounjaro. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Mounjaro and for 4 weeks after each increase in your dose of Mounjaro.

Review these questions with your healthcare provider:

  • Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
  • Do you take other diabetes medicines, such as insulin or sulfonylureas?
  • Do you have a history of diabetic retinopathy?
  • Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? It is not known if Mounjaro will harm your unborn baby or pass into your breast milk.
  • Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?

How to take

  • Read the Instructions for Use that come with Mounjaro®.
  • Use Mounjaro exactly as your healthcare provider says.
  • Mounjaro is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.
  • Use Mounjaro 1 time each week, at any time of the day.
  • Do not mix insulin and Mounjaro together in the same injection.
  • You may give an injection of Mounjaro and insulin in the same body area (such as your stomach area), but not right next to each other.
  • Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection.
  • If you take too much Mounjaro, call your healthcare provider or seek medical advice promptly.

Learn more

Mounjaro® is a prescription medicine. For more information, call 1-833-807-MJRO (833-807-6576) or go to www.mounjaro.com.

This summary provides basic information about Mounjaro but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Mounjaro and how to take it. Your healthcare provider is the best person to help you decide if Mounjaro is right for you.

Click here to visit the manufacturer's support page to make a report.

Zepbound™

Safety Information

Do not use if you have been diagnosed with the following:

  • Diabetic ketoacidosis
  • Type 1 diabetes
  • Diabetic retinopathy
  • Kidney disease
  • Multiple endocrine neoplasia syndrome type 2 (MEN 2)
  • Thyroid cancer
  • Pancreatitis

Some side effects may occur that do not require medical attention, as they may lessen as your body adjusts to the medication. You may experience more gastrointestinal (GI) side effects when you increase your dose, however it should be less over time. Reach out to your healthcare provider if you experience any unwanted side effects as there may be ways to prevent or reduce side effects. You may always reach out with any additional questions regarding your medication therapy and side effects.

More common side effects

  • acid or sour stomach
  • belching
  • constipation
  • diarrhea
  • stomach discomfort or upset
  • stomach pain
  • hypoglycemia (low blood sugar)
  • injection-site reactions
  • gallbladder disease
  • hypersensitivity reactions

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

For a full list of side effects: https://www.mayoclinic.org/drugs-supplements/tirzepatide-subcutaneous-route/side-effects/drg-20534045?p=1

Zepbound™ Safety Information:

Zepbound™ (ZEHP-bownd) is an injectable prescription medicine that may help adults with obesity, or with excess weight (overweight) who also have weight-related medical problems, lose weight and keep it off. It should be used with a reduced-calorie diet and increased physical activity.

Zepbound™ contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products. It is not known if Zepbound can be used in people who have had pancreatitis. It is not known if Zepbound is safe and effective for use in children under 18 years of age.

Warning

Zepbound™ may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

  • Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).
  • Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound.

Zepbound™ may cause serious side effects, including:

  • Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away.
  • Kidney problems (kidney failure). Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration.
  • Gallbladder problems. Gallbladder problems have happened in some people who use Zepbound. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.
  • Inflammation of the pancreas (pancreatitis). Stop using Zepbound and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back.
  • Serious allergic reactions. Stop using Zepbound and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.
  • Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery.
  • Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Zepbound.
  • Depression or thoughts of suicide. You should pay attention to changes in your mood, behaviors, feelings or thoughts. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you.

Common Side Effects

The most common side effects of Zepbound™ include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn. These are not all the possible side effects of Zepbound. Talk to your healthcare provider about any side effect that bothers you or doesn’t go away.

Tell your healthcare provider if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before using Zepbound™

  • Your healthcare provider should show you how to use Zepbound before you use it for the first time.
  • Tell your healthcare provider if you are taking medicines to treat diabetes including insulin or sulfonylureas which could increase your risk of low blood sugar. Talk to your healthcare provider about low blood sugar levels and how to manage them.
  • If you take birth control pills by mouth, talk to your healthcare provider before you use Zepbound. Birth control pills may not work as well while using Zepbound. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Zepbound™ and for 4 weeks after each increase in your dose of Zepbound.

Review these questions with your healthcare provider:

  • Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
  • Do you take diabetes medicines, such as insulin or sulfonylureas?
  • Do you have a history of diabetic retinopathy?
  • Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?
  • Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Zepbound™ may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Zepbound. It is not known if Zepbound passes into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Zepbound.

Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Zepbound™ during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Lilly at 1-800-LillyRx (1-800-545-5979).

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

For a full list of side effects: https://www.mayoclinic.org/drugs-supplements/tirzepatide-subcutaneous-route/side-effects/drg-20534045?p=1

Everyday+

Safety Information

Side effects are typically mild and go away over time.

What are the most common side effects?

  • Nausea
  • Vomiting
  • Decreased appetite
  • Dizziness
  • Headache
  • Diarrhea
  • Gastritis

Full side effect profile:

  • Low dose Naltrexone: nausea/vomiting, decreased appetite. Dizziness, headache, insomnia (can resolve in 2 weeks), vivid dreams, joint pain, muscle cramps, tooth pain, and anxiety which are all more commonly seen at higher doses
  • Inositol: nausea, vomiting, diarrhea, abdominal pain/cramps, gastritis, dizziness, high BP, decreases absorption of Iron, Ca, and Zn in bloodstream, hypoglycemia—all usually mild and go away over time. All typically seen at higher doses of 1,000-4,000mg per day.
  • L-Carnitine: nausea, vomiting, diarrhea, abdominal pain/cramps, gastritis, body odor—all usually mild and go away over time. All typically seen at higher doses of 1,000-3,000mg per day. At high doses (1,000mg-3000mg) L-Carnitine may affect the efficacy of warfarin or dicumarol.

Oral Semaglutide GLP-1

*Compounded medications may be prescribed by physicians but have not been FDA regulated for safety, effectiveness, or quality. FDA-approved medicines containing semaglutide are available.

WARNING

Please contact your doctor ASAP and seek in-person care immediately if a side effect becomes problematic or you experience:

  • Severe nausea and/or vomiting resulting in dehydration -  it is important to stay well hydrated and drink plenty of fluids while on this medication.
  • Kidney problems/kidney failure - vomiting, nausea, diarrhea can cause dehydration and kidney issues and make kidney problems worse in individuals who have pre-existing kidney conditions; may sometimes lead to the need for hemodialysis.
  • Thyroid C-Cell Tumor: Trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath (see black box warning below).
  • Pancreatitis: Severe pain in your abdomen or back that will not go away.
  • Acute gallbladder disease - Pain in the middle or right upper stomach, fever, white parts of your eyes turn yellow or skin turns yellow, nausea/vomiting. If gallstones or inflammation of the gallbladder is suspected further studies are needed.
  • Hepatitis/Elevated liver enzymes/Jaundice
  • Diabetic retinopathy problems: Changes in vision in those with type II diabetes, particularly vision problems may worsen in those with a history of diabetic retinopathy.
  • Severe gastrointestinal disease - may cause gastrointestinal disease; do not use if you have a history of severe gastrointestinal disease
  • Signs of low blood sugar (for example, dizziness, weakness, shakiness, jitteriness, headache, anxiety/mood changes, rapid heartbeat, confusion, slurred speech, sweating, or lightheadedness). While this is rare with GLP-1s, if it occurs, please seek in-person care immediately. If you have these symptoms, try having liquid or food containing sugar (around 15-20 grams) —drinking juice, having regular soda, or eating some hard candies right away, as this will help raise your blood sugar quickly. If taken with insulin or an insulin secretagogue (i.e. sulfonylurea such as Glipizide, glimepiride, and glyburide) it is best to talk to your healthcare provider about possibly lowering the dose of these medications to lower the risk of hypoglycemia.
  • Increasing heart rate
  • Worsening depression, behavior changes, or suicidality
  • Never share the semaglutide with other people

Drug Interactions

As with other medications, oral semaglutide can interact with alcohol and certain prescription and non-prescription medications and herbal products. The risk of hypoglycemia is increased when combined with insulin or insulin secretagogues such as sulfonylureas. Oral semaglutide delays gastric emptying and may impact the absorption of oral medications. If you are on thyroid hormone medication, prior to starting oral semaglutide, please review the timing of taking your thyroid hormone medication with the doctor who prescribes it as it may need to be adjusted. The drug levels of medications with narrow therapeutic windows (ie warfarin) should be monitored closely while on oral semaglutide.

Please consult the pharmaceutical packaging for a full list of side effects, warnings, interactions and additional information.

To report suspected adverse reactions to o semaglutide, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

In case of emergencies, please call 911 or go to the nearest emergency room.

Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Oral Semaglutide GLP-1

*Compounded medications may be prescribed by physicians but have not been FDA regulated for safety, effectiveness, or quality. FDA-approved medicines containing semaglutide are available.

WARNING

Please contact your doctor ASAP and seek in-person care immediately if a side effect becomes problematic or you experience:

  • Severe nausea and/or vomiting resulting in dehydration -  it is important to stay well hydrated and drink plenty of fluids while on this medication.
  • Kidney problems/kidney failure - vomiting, nausea, diarrhea can cause dehydration and kidney issues and make kidney problems worse in individuals who have pre-existing kidney conditions; may sometimes lead to the need for hemodialysis.
  • Thyroid C-Cell Tumor: Trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath (see black box warning below).
  • Pancreatitis: Severe pain in your abdomen or back that will not go away.
  • Acute gallbladder disease - Pain in the middle or right upper stomach, fever, white parts of your eyes turn yellow or skin turns yellow, nausea/vomiting. If gallstones or inflammation of the gallbladder is suspected further studies are needed.
  • Hepatitis/Elevated liver enzymes/Jaundice
  • Diabetic retinopathy problems: Changes in vision in those with type II diabetes, particularly vision problems may worsen in those with a history of diabetic retinopathy.
  • Severe gastrointestinal disease - may cause gastrointestinal disease; do not use if you have a history of severe gastrointestinal disease
  • Signs of low blood sugar (for example, dizziness, weakness, shakiness, jitteriness, headache, anxiety/mood changes, rapid heartbeat, confusion, slurred speech, sweating, or lightheadedness). While this is rare with GLP-1s, if it occurs, please seek in-person care immediately. If you have these symptoms, try having liquid or food containing sugar (around 15-20 grams) —drinking juice, having regular soda, or eating some hard candies right away, as this will help raise your blood sugar quickly. If taken with insulin or an insulin secretagogue (i.e. sulfonylurea such as Glipizide, glimepiride, and glyburide) it is best to talk to your healthcare provider about possibly lowering the dose of these medications to lower the risk of hypoglycemia.
  • Increasing heart rate
  • Worsening depression, behavior changes, or suicidality
  • Never share the semaglutide with other people
DRUG INTERACTIONS

As with other medications, oral semaglutide can interact with alcohol and certain prescription and non-prescription medications and herbal products. The risk of hypoglycemia is increased when combined with insulin or insulin secretagogues such as sulfonylureas. Oral semaglutide delays gastric emptying and may impact the absorption of oral medications. If you are on thyroid hormone medication, prior to starting oral semaglutide, please review the timing of taking your thyroid hormone medication with the doctor who prescribes it as it may need to be adjusted. The drug levels of medications with narrow therapeutic windows (ie warfarin) should be monitored closely while on oral semaglutide.

Please consult the pharmaceutical packaging for a full list of side effects, warnings, interactions and additional information.

To report suspected adverse reactions to o semaglutide, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

In case of emergencies, please call 911 or go to the nearest emergency room.

Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Important Safety Information

Wegovy®

BLACK BOX WARNING:

GLP-1s are contraindicated in individuals with a history of medullary thyroid carcinoma, a family history of such, or in patients with multiple endocrine neoplasia syndrome type 2. Do not take them if you have ever had thyroid cancer. In studies with rodents, GLP-1s caused thyroid tumors, including thyroid cancer; it is not known if they will cause thyroid tumors or cancer in humans. Please notify your doctor ASAP if you develop trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath.

If you experience a medical emergency, call 911 or go to the nearest emergency room.

Tell your healthcare provider about your medical history prior to taking Wegovy®.

Avoid alcohol while taking this medication. If you’re taking diabetes medications, please discuss this with your prescribing doctor before starting Wegovy®, as your diabetes medications may need to be adjusted as you lose weight.

Use adequate contraception while taking this medication. Do not take this medication if pregnant, trying to get pregnant or breastfeeding. If you plan to become pregnant, this medication needs to be stopped at least 2 months before trying. This medication may cause fetal harm.

Notify your doctor if you have kidney, liver, or pancreas problems.

Stop using Wegovy® and call your healthcare provider immediately if you have severe stomach or abdomen pain that will not go away, with or without vomiting.

Stop using Wegovy® and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat.

Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue Wegovy® if suspected and promptly seek medical advice.

WARNING

Please contact your doctor ASAP and seek in-person care immediately if a side effect becomes problematic or you experience:

  • Severe nausea and/or vomiting resulting in dehydration-  it is important to stay well hydrated and drink plenty of fluids while on this medication
  • Kidney problems/kidney failure - vomiting, nausea, diarrhea can cause dehydration and kidney issues and make kidney problems worse in individuals who have pre-existing kidney conditions; may sometimes lead to the need for hemodialysis
  • Thyroid C-Cell Tumor: Trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath (see black box warning below)
  • Pancreatitis: Severe pain in your abdomen or back that will not go away
  • Acute gallbladder disease - Pain in the middle or right upper stomach, fever, white parts of your eyes turn yellow or skin turns yellow, nausea/vomiting. If gallstones or inflammation of the gallbladder is suspected further studies are needed.
  • Hepatitis/Elevated liver enzymes/Jaundice
  • -Diabetic retinopathy problems: Changes in vision in those with type II diabetes, particularly vision problems may worsen in those with a history of diabetic retinopathy
  • Severe gastrointestinal disease - may cause gastrointestinal disease; do not use if you have a history of severe gastrointestinal disease
  • Signs of low blood sugar (for example, dizziness, weakness, shakiness, jitteriness, headache, anxiety/mood changes, rapid heartbeat, confusion, slurred speech, sweating, or lightheadedness). While this is rare with GLP-1s, if it occurs, please seek in-person care immediately. If you have these symptoms, try having liquid or food containing sugar (around 15-20 grams) —drinking juice, having regular soda, or eating some hard candies right away, as this will help raise your blood sugar quickly. If taken with insulin or an insulin secretagogue (ie sulfonylurea) it is best to talk to your healthcare provider about possibly lowering the dose of these medications to lower the risk of hypoglycemia.
  • Increasing heart rate
  • Worsening depression, behavior changes, or suicidality
  • Never share the Wegovy® pen with other people

SIDE EFFECTS

Many people experience no side effects. Some of the most common or potential side effects include:

  • Nausea
  • Constipation
  • Vomiting
  • Diarrhea
  • Abdominal Pain
  • Headache
  • Indigestion
  • Injection site reactions
  • Dizziness
  • Back pain
  • Increased Lipase or Amylase
  • Altered taste
  • Nasopharyngitis (common cold)
  • Passing Gas
  • Bloating
  • Belching
  • Gastroenteritis
  • Decreased appetite
  • Fatigue
  • Gastroesophageal reflux disease
  • Low blood sugar (hypoglycemia) in those with type II diabetes
  • Upset stomach

These symptoms often subside as your body adjusts to the medications. Please notify your provider if side effects persist. For a complete list of side effects, review the medication packaging inserts.

DRUG INTERACTIONS

As with other medications, Wegovy® can interact with alcohol and certain prescription and non-prescription medications and herbal products. The risk of hypoglycemia is increased when combined with insulin or insulin secretagogues such as sulfonylureas. Wegovy® delays gastric emptying and may impact the absorption of oral medications. If you are on thyroid hormone medication, prior to starting Wegovy®, please review the timing of taking your thyroid hormone medication with the doctor who prescribes it as it may need to be adjusted. The drug levels of medications with narrow therapeutic windows (ie warfarin) should be monitored closely while on Wegovy®.

Please consult the pharmaceutical packaging for a full list of side effects, warnings, interactions and additional information.

To report suspected adverse reactions to Wegovy® contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

In case of emergencies, please call 911 or go to the nearest emergency room.

Acarbose

WARNING

Acarbose can cause a severe allergic reaction. Symptoms may include:

  • skin swelling and redness
  • hives
  • itching
  • rash
  • fever
  • trouble breathing or chest tightness
  • blistering or peeling skin
  • swelling of your mouth, face, lips, tongue, or throat

Call 911 or go to the nearest emergency room if you develop these symptoms.

Don’t take this drug again if you’ve ever had an allergic reaction to it. Taking it again could be fatal.

ALCOHOL INTERACTION WARNING

Alcohol can affect your blood sugar level. It can both increase the risk of low blood sugar (hypoglycemia) as well as increase your blood sugar levels by serving as an additional source of carbohydrates. Talk with your doctor before drinking alcohol.

WARNINGS FOR PEOPLE WITH CERTAIN HEALTH CONDITIONS

For people with diabetic ketoacidosis: Don’t take this medication if you have diabetic ketoacidosis. Diabetic ketoacidosis is a serious condition that can result in unconsciousness and potentially death. Symptoms of this condition develop slowly. They include dry mouth or being very thirsty, high blood sugar levels, and urinating frequently. If you begin vomiting and suspect you have this condition, call your doctor or go to the hospital immediately. This condition can become life-threatening within a few hours once you’re vomiting.

For people with cirrhosis or liver disease: Don’t take acarbose if you have cirrhosis or severe liver disease. Taking acarbose could make your condition worse.

For people with intestinal disease: If you have certain intestinal diseases, such as inflammatory bowel disease, colonic ulceration, or partial intestinal obstruction, or if you’re predisposed to intestinal obstruction, you shouldn’t take acarbose. Taking it could make your condition worse.

For people who take insulin or a sulfonylurea: When acarbose is taken with these other drugs, it may increase your risk for developing low blood sugar (hypoglycemia). Signs of hypoglycemia may include fast heart rate, confusion, hunger, sweating, shaking, or feeling weak and dizzy. Use glucose tablets or liquid glucose to help manage a hypoglycemic event while taking acarbose. Cane sugar (sucrose) won’t work to treat your hypoglycemia while you’re taking acarbose. Use oral glucose (dextrose) products instead.

WARNINGS FOR OTHER GROUPS

For pregnant women: Acarbose is a pregnancy category B drug. That means two things:

  1. Studies of the drug in pregnant animals have not shown risk to the fetus.
  2. There aren’t enough studies done in pregnant women to show the drug poses a risk to the fetus.

Tell your doctor if you’re pregnant or plan to become pregnant. Acarbose should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

For women who are breastfeeding: Research on lactating rats has shown small amounts of acarbose in the rat milk. It isn’t known if acarbose passes through human breast milk. You and your doctor should decide if you’ll take acarbose or breastfeed.

For children: The safety and effectiveness of acarbose in people younger than 18 years haven’t been proved.

SIDE EFFECTS

Acarbose does not cause drowsiness, but it can cause other side effects.

MORE COMMON SIDE EFFECTS

The more common side effects from using acarbose include:

  • stomach pain
  • diarrhea
  • flatulence (gas)

These side effects usually develop during the first few weeks after taking acarbose. They should decrease as you continue to take the medication, typically within a few days or a couple of weeks. Talk to your doctor or pharmacist if they’re more severe or don’t go away.

SERIOUS SIDE EFFECTS

Call your doctor right away if you have serious side effects. Call 911 if your symptoms feel life-threatening or if you think you’re having a medical emergency. Serious side effects and their symptoms can include the following:

Allergic skin reaction. Symptoms may include:

  • rash
  • redness
  • swelling of your skin

Liver problems. Symptoms may include:

yellowing of the whites of your eyes or skin

stomach swelling

pain in the upper right portion of your stomach

  • Pneumatosis cystoides intestinalis. These are gas-filled cysts on the wall of your intestines. They can cause intestinal problems, such as holes, blockage, or bleeding. Symptoms may include:
  • diarrhea
  • mucus discharge
  • rectal bleeding
  • constipation

Disclaimer: Our goal is to provide you with the most relevant and current information. However, because drugs affect each person differently, we cannot guarantee that this information includes all possible side effects. This information is not a substitute for medical advice. Always discuss possible side effects with a healthcare provider who knows your medical history.

DRUG INTERACTIONS

Acarbose oral tablet can interact with other medications, herbs, or vitamins you might be taking. An interaction is when a substance changes the way a drug works. This can be harmful or prevent the drug from working well.

To help avoid interactions, your doctor should manage all of your medications carefully. Be sure to tell your doctor about all medications, vitamins, or herbs you’re taking. To find out how this drug might interact with something else you’re taking, talk to your doctor or pharmacist.

Examples of drugs that can cause interactions with acarbose are listed below.

DIABETES DRUGS

When you take certain other diabetes drugs with acarbose, your blood sugar level can get too low, causing hypoglycemia. Signs of hypoglycemia may include fast heart rate, confusion, hunger, sweating, shaking, or feeling weak and dizzy. Examples of these drugs include:

  • sulfonylureas, such as glyburide or glimepiride
  • insulin

Note: Use glucose tablets or liquid glucose to help manage a hypoglycemic event while you’re taking acarbose. Cane sugar (sucrose) won’t work to treat hypoglycemia while you’re taking acarbose. Use oral glucose (dextrose) products instead.

THYROID DRUG

Taking levothyroxine with acarbose may affect your blood sugar level. If you take these drugs together, your doctor will adjust your diabetes medications accordingly.

ESTROGENS AND ORAL CONTRACEPTIVES

Taking certain hormonal medications with acarbose may affect your blood sugar level. Your doctor will adjust your diabetes medications accordingly. Examples of these drugs include:

  • ethinyl estradiol/norgestimate
  • ethinyl estradiol/levonorgestrel
  • ethinyl estradiol/norethindrone
  • ethinyl estradiol/drospirenone

DIURETICS (WATER PILLS)

Taking acarbose with certain drugs that cause your body to lose water may lead to your blood sugar level getting too high, resulting in hyperglycemia. Examples of these drugs include:

thiazide diuretics such as:

  • hydrochlorothiazide
  • chlorthalidone

loop diuretics such as:

  • furosemide
  • bumetanide
  • torsemide
  • triamterene

CORTICOSTEROIDS

Taking acarbose with corticosteroids may cause your blood sugar level to get too high, resulting in hyperglycemia. Examples of these drugs include:

  • hydrocortisone
  • prednisone
  • prednisolone
  • methylprednisolone

ANTIPSYCHOTIC DRUGS

Taking chlorpromazine with acarbose may cause your blood sugar level to get too high, resulting in hyperglycemia.

SEIZURE DRUGS

Taking certain seizure medications with acarbose may affect your blood sugar level. Examples of these drugs include:

  • phenytoin
  • fosphenytoin

NICOTINIC ACID

Taking niacin with acarbose can cause your blood sugar level to get too high, resulting in hyperglycemia.

SYMPATHOMIMETICS

Taking drugs called sympathomimetics with acarbose may cause your blood sugar level to get too high, resulting in hyperglycemia. Examples of these drugs include:

  • pseudoephedrine
  • phenylephrine

BLOOD PRESSURE DRUGS

Taking certain blood pressure drugs called beta-blockers with acarbose may cause your blood sugar level to get too high, resulting in hyperglycemia. It can also delay how long it takes for your blood sugar to return to normal. Beta-blockers can also mask some of the signs of low blood sugar, such as higher than normal heart rate, palpitations, and shakiness. Examples of these drugs include:

  • metoprolol
  • isoprolol
  • atenolol
  • nadolol
  • propranolol

TUBERCULOSIS DRUG

Taking isoniazid with acarbose may cause your blood sugar level to get too high, resulting in hyperglycemia.

HEART PROBLEM DRUG

Taking digoxin with acarbose can cause the levels of digoxin in your body to change. If you take these drugs together, your dose of digoxin may need to be adjusted by your doctor.

Disclaimer: Our goal is to provide you with the most relevant and current information. However, because drugs interact differently in each person, we cannot guarantee that this information includes all possible interactions. This information is not a substitute for medical advice. Always speak with your healthcare provider about possible interactions with all prescription drugs, vitamins, herbs and supplements, and over-the-counter drugs that you are taking.

To report suspected adverse reactions to acarbose contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

In case of emergencies, please call 911 or go to the nearest emergency room.

Ozempic®

BLACK BOX WARNING:

GLP-1s are contraindicated in individuals with a history of medullary thyroid carcinoma, a family history of such, or in patients with multiple endocrine neoplasia syndrome type 2. Do not take them if you have ever had thyroid cancer. In studies with rodents, GLP-1s caused thyroid tumors, including thyroid cancer; it is not known if they will cause thyroid tumors or cancer in humans. Please notify your doctor ASAP if you develop trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath.

If you experience a medical emergency, call 911 or go to the nearest emergency room.

Tell your healthcare provider about your medical history prior to taking Ozempic®.

Avoid alcohol while taking this medication. If you’re taking diabetes medications, please discuss this with your prescribing doctor before starting Ozempic®, as your diabetes medications may need to be adjusted as you lose weight.

Use adequate contraception while taking this medication. Do not take this medication if pregnant, trying to get pregnant or breastfeeding. If you plan to become pregnant, this medication needs to be stopped at least 2 months before trying. This medication may cause fetal harm.

Notify your doctor if you have kidney, liver, or pancreas problems.

Stop using Ozempic® and call your healthcare provider immediately if you have severe stomach or abdomen pain that will not go away, with or without vomiting.

Stop using Ozempic® and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat.

Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue Ozempic® if suspected and promptly seek medical advice.

WARNING

Please contact your doctor ASAP and seek in-person care immediately if a side effect becomes problematic or you experience:

  • Severe nausea and/or vomiting resulting in dehydration-  it is important to stay well hydrated and drink plenty of fluids while on this medication
  • Kidney problems/kidney failure - vomiting, nausea, diarrhea can cause dehydration and kidney issues and make kidney problems worse in individuals who have pre-existing kidney conditions; may sometimes lead to the need for hemodialysis
  • Thyroid C-Cell Tumor: Trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath (see black box warning below)
  • Pancreatitis: Severe pain in your abdomen or back that will not go away
  • Acute gallbladder disease - Pain in the middle or right upper stomach, fever, white parts of your eyes turn yellow or skin turns yellow, nausea/vomiting. If gallstones or inflammation of the gallbladder is suspected further studies are needed.
  • Hepatitis/Elevated liver enzymes/Jaundice
  • Diabetic retinopathy problems: Changes in vision in those with type II diabetes, particularly vision problems may worsen in those with a history of diabetic retinopathy
  • Severe gastrointestinal disease - may cause gastrointestinal disease; do not use if you have a history of severe gastrointestinal disease
  • Signs of low blood sugar (for example, dizziness, weakness, shakiness, jitteriness, headache, anxiety/mood changes, rapid heartbeat, confusion, slurred speech, sweating, or lightheadedness). While this is rare with GLP-1s, if it occurs, please seek in-person care immediately. If you have these symptoms, try having liquid or food containing sugar (around 15-20 grams) —drinking juice, having regular soda, or eating some hard candies right away, as this will help raise your blood sugar quickly. If taken with insulin or an insulin secretagogue (ie sulfonylurea) it is best to talk to your healthcare provider about possibly lowering the dose of these medications to lower the risk of hypoglycemia.
  • Increasing heart rate
  • Worsening depression, behavior changes, or suicidality
  • Never share the Ozempic® pen with other people

SIDE EFFECTS

Many people experience no side effects. Some of the most common or potential side effects include:

  • Nausea
  • Constipation
  • Vomiting
  • Diarrhea
  • Abdominal Pain
  • Headache
  • Indigestion
  • Injection site reactions
  • Dizziness
  • Back pain
  • Increased Lipase or Amylase
  • Altered taste
  • Nasopharyngitis (common cold)
  • Passing Gas
  • Bloating
  • Belching
  • Gastroenteritis
  • Decreased appetite
  • Fatigue
  • Gastroesophageal reflux disease
  • Low blood sugar (hypoglycemia) in those with type II diabetes
  • Upset stomach

These symptoms often subside as your body adjusts to the medications. Please notify your provider if side effects persist. For a complete list of side effects, review the medication packaging inserts.

DRUG INTERACTIONS

As with other medications, Ozempic® can interact with alcohol and certain prescription and non-prescription medications and herbal products. The risk of hypoglycemia is increased when combined with insulin or insulin secretagogues such as sulfonylureas. Ozempic® delays gastric emptying and may impact the absorption of oral medications. If you are on thyroid hormone medication, prior to starting Ozempic®, please review the timing of taking your thyroid hormone medication with the doctor who prescribes it as it may need to be adjusted. The drug levels of medications with narrow therapeutic windows (ie warfarin) should be monitored closely while on Ozempic®.

Please consult the pharmaceutical packaging for a full list of side effects, warnings, interactions and additional information.

To report suspected adverse reactions to Ozempic® contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

In case of emergencies, please call 911 or go to the nearest emergency room.

Naltrexone

WARNING

DO NOT take naltrexone if you are taking ANY opioids or opiate drugs or if you are dependent on opioids or using methadone or buprenorphine, or if you are in opioid withdrawal. If you take opioids/opiates right after stopping naltrexone you may be more sensitive to them (and require lower doses) - which poses a risk of overdose. Please talk to your provider before initiating any amount of opioids/opiates after stopping naltrexone. Do not take this medication if you have a sensitivity to it or any of its components.

Before using naltrexone, tell your healthcare provider about your medical history, especially if you have:

  • kidney disease
  • liver disease (as it may cause liver dysfunction or hepatitis)
  • depression/suicidality
  • current or recent (7-14 days) use of any type of opioid or opiate drugs

This drug may make you dizzy or drowsy or impair your judgment. Please do not drive, operate heavy machinery, or perform any hazardous task until the effects of naltrexone are known to you. For anyone taking diabetes medications, please have a discussion with your prescribing clinician prior to taking naltrexone as your diabetes medications may need to be adjusted as you lose weight. You should wear medical identification stating that you are taking this drug so that appropriate treatment can be given in a medical emergency.

Tell your healthcare provider right away if you experience severe stomach or abdominal pain changes in vision, eye pain, burning or swollen eyes, chest pain, confusion, discomfort while urinating or frequent urination, fever, hallucinations or seeing, hearing, or feeling things that are not there, itching, mental depression or other mood or mental changes or suicidality, ringing or buzzing in the ears, shortness of breath, swelling of the face, feet, or lower legs or weight gain.

DO NOT take naltrexone if you are planning to become pregnant or if pregnant or breastfeeding.

SIDE EFFECTS

Many people experience no side effects while taking naltrexone. Some of the most common side effects (but not extremely frequent) are:

  • fatigue or low energy
  • difficulty sleeping
  • nervousness and anxiety
  • headache
  • nausea or vomiting
  • joint and muscle pain
  • stomach cramps or pain

Additional side effects include:

  • loss of appetite
  • diarrhea or constipation
  • increased energy
  • increased thirst
  • dizziness
  • skin rash
  • sexual problems in males
  • chills
  • runny nose
  • irritability or feeling down

These symptoms may subside after the body adjusts to the medication.

DRUG INTERACTIONS

As with other medications, naltrexone can interact with certain prescription and non-prescription medications and herbal products, including dextromethorphan, diarrhea medication, disulfiram, opioid pain or cough relievers (such as codeine) and thioridazine.
Please consult the pharmaceutical packaging for a full list of side effects, warnings, interactions and additional information.

To report suspected adverse reactions to naltrexone contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

In case of emergencies, please call 911 or go to the nearest emergency room.

Orlistat

WARNING

Do not use orlistat if you have had an organ transplant because the medicine interferes with the medicines used to prevent transplant rejection. There have been rare reports of liver injury in people taking orlistat.

Before using orlistat tell your healthcare provider about your medical history, especially if you have:

  • gallbladder problems
  • kidney stones
  • pancreatitis

Ask your healthcare provider before you use orlistat if you are taking any of the following prescription medications:

  • anticoagulants (blood thinning medicine)
  • amiodarone (heart medicine)
  • diabetes medicine
  • thyroid disease medicine
  • seizure medicine (for a seizure disorder)
  • antiretrovirals (HIV medicine)
  • taking any other weight loss products

You should not take orlistat if you are planning to become pregnant or if pregnant or breastfeeding. Do not use orlistat if you are not overweight or if you have been diagnosed with problems absorbing food. When using this medication, you should also take a multivitamin once a day at bedtime, and follow a well-balanced, reduced-calorie, low-fat diet. If you have any serious side effects, including, itching, yellow eyes or skin, dark urine, loss of appetite, severe or continuous abdominal pain, hives, vomiting, chest pain, rectal bleeding, constipation that lasts more than 7 days, difficulty swallowing or breathing, or you are taking medicine for seizures and your seizures happen more often or get worse, stop using the medication and talk to your healthcare provider.

SIDE EFFECTS

Many people experience no side effects while taking orlistat. Some of the most common side effects (but not extremely frequent) are:

  • diarrhea
  • oily stools or spotting
  • stomach discomfort
  • gas
  • more frequent bowel movements that may be hard to control

Additional side effects include:

  • loss of appetite
  • diarrhea or constipation
  • increased energy
  • increased thirst
  • dizziness
  • skin rash
  • sexual problems in males
  • chills
  • runny nose
  • irritability or feeling down

These symptoms may subside after the body adjusts to the medication.

DRUG INTERACTIONS

Please consult the pharmaceutical packaging for a full list of side effects, warnings, interactions and additional information.

To report suspected adverse reactions, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

In case of emergencies, please call 911 or go to the nearest emergency room.

Semaglutide + B12

WARNING

Please contact your doctor ASAP and seek in-person care immediately if a side effect becomes problematic or you experience:

  • Severe nausea and/or vomiting resulting in dehydration -  it is important to stay well hydrated and drink plenty of fluids while on this medication
  • Kidney problems/kidney failure - vomiting, nausea, diarrhea can cause dehydration and kidney issues and make kidney problems worse in individuals who have pre-existing kidney conditions; may sometimes lead to the need for hemodialysis
  • Thyroid C-Cell Tumor: Trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath (see black box warning below)
  • Pancreatitis: Severe pain in your abdomen or back that will not go away
  • Acute gallbladder disease - Pain in the middle or right upper stomach, fever, white parts of your eyes turn yellow or skin turns yellow, nausea/vomiting. If gallstones or inflammation of the gallbladder is suspected further studies are needed.
  • Hepatitis/Elevated liver enzymes/Jaundice
  • Diabetic retinopathy problems: Changes in vision in those with type II diabetes, particularly vision problems may worsen in those with a history of diabetic retinopathy
  • Severe gastrointestinal disease - may cause gastrointestinal disease; do not use if you have a history of severe gastrointestinal disease
  • Signs of low blood sugar (for example, dizziness, weakness, shakiness, jitteriness, headache, anxiety/mood changes, rapid heartbeat, confusion, slurred speech, sweating, or lightheadedness)
  • While this is rare with GLP-1s, if it occurs, please seek in-person care immediately. If you have these symptoms, try having liquid or food containing sugar (around 15-20 grams) —drinking juice, having regular soda, or eating some hard candies right away, as this will help raise your blood sugar quickly. If taken with insulin or an insulin secretagogue (ie sulfonylurea) it is best to talk to your healthcare provider about possibly lowering the dose of these medications to lower the risk of hypoglycemia.
  • Increasing heart rate
  • Worsening depression, behavior changes, or suicidality
    Never share the semaglutide with other people

Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

BLACK BOX WARNING:

GLP-1s are contraindicated in individuals with a history of medullary thyroid carcinoma, a family history of such, or in patients with multiple endocrine neoplasia syndrome type 2. Do not take them if you have ever had thyroid cancer. In studies with rodents, GLP-1s caused thyroid tumors, including thyroid cancer; it is not known if they will cause thyroid tumors or cancer in humans. Please notify your doctor ASAP if you develop trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath.

If you experience a medical emergency, call 911 or go to the nearest emergency room.

Tell your healthcare provider about your medical history prior to taking semaglutide.

Avoid alcohol while taking this medication. If you’re taking diabetes medications, please discuss this with your prescribing doctor before starting semaglutide, as your diabetes medications may need to be adjusted as you lose weight.

Use adequate contraception while taking this medication. Do not take this medication if pregnant, trying to get pregnant or breastfeeding. If you plan to become pregnant, this medication needs to be stopped at least 2 months before trying. This medication may cause fetal harm.

Notify your doctor if you have kidney, liver, or pancreas problems.

Stop using semaglutide and call your healthcare provider immediately if you have severe stomach or abdomen pain that will not go away, with or without vomiting.

Stop using semaglutide and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat.

Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue semaglutide if suspected and promptly seek medical advice.

Ozempic®

BLACK BOX WARNING:

GLP-1s are contraindicated in individuals with a history of medullary thyroid carcinoma, a family history of such, or in patients with multiple endocrine neoplasia syndrome type 2. Do not take them if you have ever had thyroid cancer. In studies with rodents, GLP-1s caused thyroid tumors, including thyroid cancer; it is not known if they will cause thyroid tumors or cancer in humans. Please notify your doctor ASAP if you develop trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath.

If you experience a medical emergency, call 911 or go to the nearest emergency room.

Tell your healthcare provider about your medical history prior to taking Ozempic®.

Avoid alcohol while taking this medication. If you’re taking diabetes medications, please discuss this with your prescribing doctor before starting Ozempic®, as your diabetes medications may need to be adjusted as you lose weight.

Use adequate contraception while taking this medication. Do not take this medication if pregnant, trying to get pregnant or breastfeeding. If you plan to become pregnant, this medication needs to be stopped at least 2 months before trying. This medication may cause fetal harm.

Notify your doctor if you have kidney, liver, or pancreas problems.

Stop using Ozempic® and call your healthcare provider immediately if you have severe stomach or abdomen pain that will not go away, with or without vomiting.

Stop using Ozempic® and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat.

Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue Ozempic® if suspected and promptly seek medical advice.

WARNING

Please contact your doctor ASAP and seek in-person care immediately if a side effect becomes problematic or you experience:

  • Severe nausea and/or vomiting resulting in dehydration-  it is important to stay well hydrated and drink plenty of fluids while on this medication
  • Kidney problems/kidney failure - vomiting, nausea, diarrhea can cause dehydration and kidney issues and make kidney problems worse in individuals who have pre-existing kidney conditions; may sometimes lead to the need for hemodialysis
  • Thyroid C-Cell Tumor: Trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath (see black box warning below)
  • Pancreatitis: Severe pain in your abdomen or back that will not go away
  • Acute gallbladder disease - Pain in the middle or right upper stomach, fever, white parts of your eyes turn yellow or skin turns yellow, nausea/vomiting. If gallstones or inflammation of the gallbladder is suspected further studies are needed.
  • Hepatitis/Elevated liver enzymes/Jaundice
  • Diabetic retinopathy problems: Changes in vision in those with type II diabetes, particularly vision problems may worsen in those with a history of diabetic retinopathy
  • Severe gastrointestinal disease - may cause gastrointestinal disease; do not use if you have a history of severe gastrointestinal disease
  • Signs of low blood sugar (for example, dizziness, weakness, shakiness, jitteriness, headache, anxiety/mood changes, rapid heartbeat, confusion, slurred speech, sweating, or lightheadedness). While this is rare with GLP-1s, if it occurs, please seek in-person care immediately. If you have these symptoms, try having liquid or food containing sugar (around 15-20 grams) —drinking juice, having regular soda, or eating some hard candies right away, as this will help raise your blood sugar quickly. If taken with insulin or an insulin secretagogue (ie sulfonylurea) it is best to talk to your healthcare provider about possibly lowering the dose of these medications to lower the risk of hypoglycemia.
  • Increasing heart rate
  • Worsening depression, behavior changes, or suicidality
  • Never share the Ozempic® pen with other people

Side Effects

Many people experience no side effects. Some of the most common or potential side effects include:

  • Nausea
  • Constipation
  • Vomiting
  • Diarrhea
  • Abdominal Pain
  • Headache
  • Indigestion
  • Injection site reactions
  • Dizziness
  • Back pain
  • Increased Lipase or Amylase
  • Altered taste
  • Nasopharyngitis (common cold)
  • Passing Gas
  • Bloating
  • Belching
  • Gastroenteritis
  • Decreased appetite
  • Fatigue
  • Gastroesophageal reflux disease
  • Low blood sugar (hypoglycemia) in those with type II diabetes
  • Upset stomach

These symptoms often subside as your body adjusts to the medications. Please notify your provider if side effects persist. For a complete list of side effects, review the medication packaging inserts.

Drug Interactions

As with other medications, Ozempic® can interact with alcohol and certain prescription and non-prescription medications and herbal products. The risk of hypoglycemia is increased when combined with insulin or insulin secretagogues such as sulfonylureas. Ozempic® delays gastric emptying and may impact the absorption of oral medications. If you are on thyroid hormone medication, prior to starting Ozempic®, please review the timing of taking your thyroid hormone medication with the doctor who prescribes it as it may need to be adjusted. The drug levels of medications with narrow therapeutic windows (ie warfarin) should be monitored closely while on Ozempic®.

Please consult the pharmaceutical packaging for a full list of side effects, warnings, interactions and additional information.

To report suspected adverse reactions to Ozempic® contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

In case of emergencies, please call 911 or go to the nearest emergency room.

Wegovy®

BLACK BOX WARNING:

GLP-1s are contraindicated in individuals with a history of medullary thyroid carcinoma, a family history of such, or in patients with multiple endocrine neoplasia syndrome type 2. Do not take them if you have ever had thyroid cancer. In studies with rodents, GLP-1s caused thyroid tumors, including thyroid cancer; it is not known if they will cause thyroid tumors or cancer in humans. Please notify your doctor ASAP if you develop trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath.

If you experience a medical emergency, call 911 or go to the nearest emergency room.

Tell your healthcare provider about your medical history prior to taking Wegovy®.

Avoid alcohol while taking this medication. If you’re taking diabetes medications, please discuss this with your prescribing doctor before starting Wegovy®, as your diabetes medications may need to be adjusted as you lose weight.

Use adequate contraception while taking this medication. Do not take this medication if pregnant, trying to get pregnant or breastfeeding. If you plan to become pregnant, this medication needs to be stopped at least 2 months before trying. This medication may cause fetal harm.

Notify your doctor if you have kidney, liver, or pancreas problems.

Stop using Wegovy® and call your healthcare provider immediately if you have severe stomach or abdomen pain that will not go away, with or without vomiting.

Stop using Wegovy® and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat.

Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue Wegovy® if suspected and promptly seek medical advice.

WARNING

Please contact your doctor ASAP and seek in-person care immediately if a side effect becomes problematic or you experience:

  • Severe nausea and/or vomiting resulting in dehydration-  it is important to stay well hydrated and drink plenty of fluids while on this medication
  • Kidney problems/kidney failure - vomiting, nausea, diarrhea can cause dehydration and kidney issues and make kidney problems worse in individuals who have pre-existing kidney conditions; may sometimes lead to the need for hemodialysis
  • Thyroid C-Cell Tumor: Trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath (see black box warning below)
  • Pancreatitis: Severe pain in your abdomen or back that will not go away
  • Acute gallbladder disease - Pain in the middle or right upper stomach, fever, white parts of your eyes turn yellow or skin turns yellow, nausea/vomiting. If gallstones or inflammation of the gallbladder is suspected further studies are needed.
  • Hepatitis/Elevated liver enzymes/Jaundice
  • -Diabetic retinopathy problems: Changes in vision in those with type II diabetes, particularly vision problems may worsen in those with a history of diabetic retinopathy
  • Severe gastrointestinal disease - may cause gastrointestinal disease; do not use if you have a history of severe gastrointestinal disease
  • Signs of low blood sugar (for example, dizziness, weakness, shakiness, jitteriness, headache, anxiety/mood changes, rapid heartbeat, confusion, slurred speech, sweating, or lightheadedness). While this is rare with GLP-1s, if it occurs, please seek in-person care immediately. If you have these symptoms, try having liquid or food containing sugar (around 15-20 grams) —drinking juice, having regular soda, or eating some hard candies right away, as this will help raise your blood sugar quickly. If taken with insulin or an insulin secretagogue (ie sulfonylurea) it is best to talk to your healthcare provider about possibly lowering the dose of these medications to lower the risk of hypoglycemia.
  • Increasing heart rate
  • Worsening depression, behavior changes, or suicidality
  • Never share the Wegovy® pen with other people

Side Effects

Many people experience no side effects. Some of the most common or potential side effects include:

  • Nausea
  • Constipation
  • Vomiting
  • Diarrhea
  • Abdominal Pain
  • Headache
  • Indigestion
  • Injection site reactions
  • Dizziness
  • Back pain
  • Increased Lipase or Amylase
  • Altered taste
  • Nasopharyngitis (common cold)
  • Passing Gas
  • Bloating
  • Belching
  • Gastroenteritis
  • Decreased appetite
  • Fatigue
  • Gastroesophageal reflux disease
  • Low blood sugar (hypoglycemia) in those with type II diabetes
  • Upset stomach

These symptoms often subside as your body adjusts to the medications. Please notify your provider if side effects persist. For a complete list of side effects, review the medication packaging inserts.

Drug Interactions

As with other medications, Wegovy® can interact with alcohol and certain prescription and non-prescription medications and herbal products. The risk of hypoglycemia is increased when combined with insulin or insulin secretagogues such as sulfonylureas. Wegovy® delays gastric emptying and may impact the absorption of oral medications. If you are on thyroid hormone medication, prior to starting Wegovy®, please review the timing of taking your thyroid hormone medication with the doctor who prescribes it as it may need to be adjusted. The drug levels of medications with narrow therapeutic windows (ie warfarin) should be monitored closely while on Wegovy®.

Please consult the pharmaceutical packaging for a full list of side effects, warnings, interactions and additional information.

To report suspected adverse reactions to Wegovy® contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

In case of emergencies, please call 911 or go to the nearest emergency room.

Compounded Semaglutide

*Compounded medications may be prescribed by physicians but have not been FDA regulated for safety, effectiveness, or quality. FDA-approved medicines containing semaglutide are available.

WARNING

Please contact your doctor ASAP and seek in-person care immediately if a side effect becomes problematic or you experience:

  • Severe nausea and/or vomiting resulting in dehydration—it is important to stay well hydrated and drink plenty of fluids while on this medication
    Kidney problems/kidney failure - vomiting, nausea, diarrhea can cause dehydration and kidney issues and make kidney problems worse in individuals who have pre-existing kidney conditions; may sometimes lead to the need for hemodialysis
  • Thyroid C-Cell Tumor: Trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath (see black box warning below)
  • Pancreatitis: Severe pain in your abdomen or back that will not go away
  • Acute gallbladder disease - Pain in the middle or right upper stomach, fever, white parts of your eyes turn yellow or skin turns yellow, nausea/vomiting. If gallstones or inflammation of the gallbladder is suspected further studies are needed.
  • Hepatitis/Elevated liver enzymes/Jaundice
  • Diabetic retinopathy problems: Changes in vision in those with type II diabetes, particularly vision problems may worsen in those with a history of diabetic retinopathy
  • Severe gastrointestinal disease - may cause gastrointestinal disease; do not use if you have a history of severe gastrointestinal disease
  • Signs of low blood sugar (for example, dizziness, weakness, shakiness, jitteriness, headache, anxiety/mood changes, rapid heartbeat, confusion, slurred speech, sweating, or lightheadedness). While this is rare with GLP-1s, if it occurs, please seek in-person care immediately. If you have these symptoms, try having liquid or food containing sugar (around 15-20 grams) —drinking juice, having regular soda, or eating some hard candies right away, as this will help raise your blood sugar quickly. If taken with insulin or an insulin secretagogue (i.e. sulfonylurea such as Glipizide, glimepiride, and glyburide) it is best to talk to your healthcare provider about possibly lowering the dose of these medications to lower the risk of hypoglycemia.
  • Increasing heart rate
  • Worsening depression, behavior changes, or suicidality

Never share the semaglutide with other people

Drug Interactions

As with other medications, compounded semaglutide can interact with alcohol and certain prescription and non-prescription medications and herbal products. The risk of hypoglycemia is increased when combined with insulin or insulin secretagogues such as sulfonylureas. Compounded semaglutide delays gastric emptying and may impact the absorption of oral medications. If you are on papillary hormone medication, prior to starting compounded semaglutide, please review the timing of taking your papillary hormone medication with the doctor who prescribes it as it may need to be adjusted. The drug levels of medications with narrow therapeutic windows (ie warfarin) should be monitored closely while on compounded semaglutide.

Please consult the pharmaceutical packaging for a full list of side effects, warnings, interactions and additional information.

To report suspected adverse reactions to compounded semaglutide, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

In case of emergencies, please call 911 or go to the nearest emergency room.

Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

BLACK BOX WARNING

GLP-1s are contraindicated in individuals with a history of medullary thyroid carcinoma, a family history of such, or in patients with multiple endocrine neoplasia syndrome type 2. Do not take them if you have ever had thyroid cancer. In studies with rodents, GLP-1s caused thyroid tumors, including thyroid cancer; it is not known if they will cause thyroid tumors or cancer in humans. Please notify your doctor ASAP if you develop trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath.

If you experience a medical emergency, call 911 or go to the nearest emergency room.

Tell your healthcare provider about your medical history prior to taking semaglutide.

Avoid alcohol while taking this medication. If you’re taking diabetes medications, please discuss this with your prescribing doctor before starting semaglutide, as your diabetes medications may need to be adjusted as you lose weight.

Use adequate contraception while taking this medication. Do not take this medication if pregnant, trying to get pregnant or breastfeeding. If you plan to become pregnant, this medication needs to be stopped at least 2 months before trying. This medication may cause fetal harm.

Notify your doctor if you have kidney, liver, or pancreas problems.

Stop using semaglutide and call your healthcare provider immediately if you have severe stomach or abdomen pain that will not go away, with or without vomiting.

Stop using semaglutide and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat.

Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue semaglutide if suspected and promptly seek medical advice.